A0A679G4D8 (A0A679G4D8_SARS2) Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
ORF1ab polyprotein UniProtKBInterProInteractive Modelling
7096 aa; Sequence (Fasta) ;
3 identical sequences: Severe acute respiratory syndrome coronavirus 2: P0DTD1, A0A6B9V049, A0A6V7ALW7
It is possible new templates exist for this target since these models were created.
Available Structures
2267 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| SARS-CoV-2 Mpro mutant (H41A) in complex with nsp15|16 peptidyl substrate |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 15/16 |
Heteromer P0DTD1; | 3×GOL; | ||||
| Assess | ||||||
| SARS-CoV-2 Mpro mutant (H41A) in complex with nsp14|15 peptidyl substrate |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Crystal Structure of Nsp16-Nsp10 from SARS-CoV-2 in Complex with 7-methyl-GpppA and S-Adenosylmethi… |
Heteromer P0DTD1; | 14×CL; 1×SAM; 1×GTA; 1×MGP; 2×ADE; 10×SO4; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Nsp16/10 Heterodimer in Complex with (m7GpppA)pUpUpApApA (Cap-0) an… |
Heteromer P0DTD1; | 1×SAM; 1×MG; 1×NA; 1×CL; 4×FMT; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of Nsp16-Nsp10 Heterodimer from SARS-CoV-2 in Complex with 7-methyl-GpppA and S-a… |
Heteromer P0DTD1; | 1×SAH; 1×GTA; 1×M7G; 8×SO4; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Nsp16/10 Heterodimer in Complex with (m7GpppA2m)pUpUpApApA (Cap-1) … |
Heteromer P0DTD1; | 1×SAH; 2×NA; 2×CL; 6×FMT; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of Nsp16-Nsp10 Heterodimer from SARS-CoV-2 with 7-methyl-GpppA and S-adenosyl-L-h… |
Heteromer P0DTD1; | 1×SAH; 1×GTA; 1×MGP; 10×SO4; 4×CL; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 methyltransferase nsp10-16 in complex with Toyocamycin and m7GpppA (Cap0-analog) |
Heteromer P0DTD1; | 1×TO1; 1×GTA; 1×MGP; 2×EDO; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with adenosine |
Heteromer P0DTD1; | 1×ADN; 39×EDO; 1×MES; 1×CL; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 methyltransferase nsp10-16 in complex with SAM and m7GpppA (Cap0-analog)/m7GpppAm (Cap1-… |
Heteromer P0DTD1; | 1×GTA; 13×EDO; 1×SAM; 1×MES; 1×EDT; 1×V9G; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with ADP |
Heteromer P0DTD1; | 31×EDO; 1×MES; 1×ADP; 1×SAM; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with SAM analog BDH 33959089 |
Heteromer P0DTD1; | 28×EDO; 1×MES; 1×SAM; 1×W08; 1×CL; 2×ZN; | ||||
| Assess | ||||||
| 1.80 Angstrom Resolution Crystal Structure of NSP16 - NSP10 Complex from SARS-CoV-2 |
Heteromer P0DTD1; | 1×SO3; 1×SAM; 2×ACT; 2×BDF; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with AMP |
Heteromer P0DTD1; | 28×EDO; 1×MES; 1×AMP; 2×ZN; 1×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 nsp16/nsp10 in complex with RNA cap analogue (m7GpppA) and S-adenosylmethio… |
Heteromer P0DTD1; | 1×SAM; 1×ADN; 1×GTA; 2×ZN; 1×EDO; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with 5-Iodotubercidin |
Heteromer P0DTD1; | 21×EDO; 1×MES; 1×5ID; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with ATP |
Heteromer P0DTD1; | 1×ATP; 30×EDO; 1×MES; 1×SAM; 2×CL; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Nsp16/10 Heterodimer Apo-Form. |
Heteromer P0DTD1; | 4×NA; 7×FMT; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with MTA |
Heteromer P0DTD1; | 33×EDO; 1×MES; 1×MTA; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with Toyocamycin |
Heteromer P0DTD1; | 22×EDO; 1×MES; 1×TO1; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with tubercidin |
Heteromer P0DTD1; | 31×EDO; 1×MES; 1×TBN; 2×CL; 2×ZN; | ||||
| Assess | ||||||
| 1.95 Angstrom Resolution Crystal Structure of NSP10 - NSP16 Complex from SARS-CoV-2 |
Heteromer P0DTD1; | 2×NA; 1×SAM; 9×FMT; 2×ZN; | ||||
| Assess | ||||||
| 1.98 Angstrom Resolution Crystal Structure of NSP16-NSP10 Heterodimer from SARS-CoV-2 in Complex wi… |
Heteromer P0DTD1; | 2×NA; 1×SFG; 6×FMT; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with Toyocamycin and m7GpppA-RNA (Cap0-RNA) |
Heteromer P0DTD1; | 1×MES; 1×TO1; 1×MG; 2×ZN; 1×GTA; | ||||
| Assess | ||||||
| 2.0 Angstrom Resolution Crystal Structure of Nsp16-Nsp10 Heterodimer from SARS-CoV-2 in Complex wit… |
Heteromer P0DTD1; | 1×NA; 1×SAH; 8×FMT; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of the methyltransferase-stimulatory factor complex of NSP16 and NSP10 from SARS … |
Heteromer P0DTD1; | 1×CL; 3×EDO; 1×SAM; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with Sangivamycin and m7GpppA-RNA (Cap0-RNA) |
Heteromer P0DTD1; | 1×MES; 1×SAM; 1×SGV; 3×EDO; 2×ZN; 1×GTA; | ||||
| Assess | ||||||
| Room Temperature Structure of SARS-CoV-2 Nsp10/Nsp16 Methyltransferase in a Complex with m7GpppA Ca… |
Heteromer P0DTD1; | 1×GTA; 1×SAM; 1×M7G; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with MTA and glycine |
Heteromer P0DTD1; | 25×EDO; 1×MES; 1×MTA; 1×GLY; 2×ZN; | ||||
| Assess | ||||||
| Room Temperature Structure of SARS-CoV-2 NSP10/NSP16 Methyltransferase in a Complex with SAM Determ… |
Heteromer P0DTD1; | 1×CL; 1×SAM; 2×ZN; | ||||
| Assess | ||||||
| Room Temperature Structure of SARS-CoV-2 Nsp10/Nsp16 Methyltransferase in a Complex with 2'-O-methy… |
Heteromer P0DTD1; | 1×CL; 1×SAH; 1×V9G; 1×MGP; 2×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 nsp16/nsp10 complex in presence of Cap-1 analog (m7GpppAmU) and SAH |
Heteromer P0DTD1; | 1×MES; 1×MG; 1×SAH; 1×YG4; 1×EDO; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with Sangivamycin and m7GpppA (Cap0-analog)/m7Gppp… |
Heteromer P0DTD1; | 1×SGV; 1×GTA; 1×MES; 1×SAH; 8×EDO; 1×V9G; 2×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 nsp16/nsp10 complex in presence of S-adenosyl-L-homocysteine (SAH) |
Heteromer P0DTD1; | 1×MES; 9×ACT; 3×EDO; 1×SAH; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of nsp16-nsp10 heterodimer from SARS-CoV-2 in complex with SAM (with additional S… |
Heteromer P0DTD1; | 1×SAM; 2×ZN; | ||||
| Assess | ||||||
| Room Temperature Crystal Structure of Nsp10/Nsp16 from SARS-CoV-2 with Substrates and Products of 2… |
Heteromer P0DTD1; | 2×CL; 1×SAM; 1×SAH; 1×GTA; 1×V9G; 1×MGP; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Nsp16/10 Heterodimer in Complex with (m7GpppA2m)pUpUpApApA (Cap-1),… |
Heteromer P0DTD1; | 2×MG; 1×CL; 1×FMT; 1×SAH; 2×GLC; 2×ZN; 1×BDF; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp10-16 methyltransferase in complex with Sangivamycin |
Heteromer P0DTD1; | 22×EDO; 1×MES; 1×SGV; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Nsp16/10 Heterodimer in Complex with (m7GpppA2m)pUpUpApApA (Cap-1),… |
Heteromer P0DTD1; | 1×MN; 2×CL; 1×SO4; 1×SAH; 4×GLC; 1×ZN; 1×BDF; | ||||
| Assess | ||||||
| Crystal structure of 2019-nCoV nsp16-nsp10 complex |
Heteromer P0DTD1; | 1×SAM; 2×ZN; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 nsp10-nsp16 methyltransferase complex with Sinefungin |
Heteromer P0DTD1; | 1×SFG; 1×MES; 2×ZN; | ||||
| Assess | ||||||
| Room Temperature Structure of SARS-CoV-2 Nsp10/16 Methyltransferase in a Complex with Cap-0 and SAM… |
Heteromer P0DTD1; | 2×GTA; 1×SAM; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 nsp10/nsp16 in complex with the WZ16 inhibitor |
Heteromer P0DTD1; | 1×4IK; 1×GTA; 1×MES; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 nsp10/nsp16 in complex with the SS148 inhibitor |
Heteromer P0DTD1; | 1×6NR; 2×PO4; 1×MES; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of nsp16-nsp10 heterodimer from SARS-CoV-2 in complex with SAM (without additiona… |
Heteromer P0DTD1; | 1×SAM; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 nsp10/nsp16 complex with bound SAH |
Heteromer P0DTD1; | 2×GOL; 1×SAH; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 2'-O-Methyltransferase in Complex with Compound 5a covalently bound… |
Heteromer P0DTD1; | 2×NA; 1×XDU; 3×XE0; 10×FMT; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of the SARS-CoV-2 2'-O-Methyltransferase with Compound 5a bound to the Cryptic Po… |
Heteromer P0DTD1; | 1×NA; 1×XDU; 5×FMT; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 nsp10/nsp16 methyltransferase in complex with TO383 |
Heteromer P0DTD1; | 1×KW6; 1×GOL; 2×ZN; | ||||
| Assess | ||||||
| Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 13/14 |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Co-transcriptional capping machineries in SARS-CoV-2 RTC: Coupling of N7-methyltransferase and 3'-5… |
Heteromer P0DTD1; | 26×ZN; 3×MG; | ||||
| Assess | ||||||
| Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mecha… |
Heteromer P0DTC1; P0DTD1; | 13×ZN; 1×MG; | ||||
| Assess | ||||||
| Cryo-EM structure of the tetrameric form of SARS-CoV-2 nsp10-nsp14 (E191A)-RNA complex |
Heteromer P0DTD1; | 20×ZN; 6×MG; 2×1N7; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 nsp10-nsp14 (WT)-RNA complex |
Heteromer P0DTD1; | 5×ZN; 2×CA; | ||||
| Assess | ||||||
| Cryo-EM structure of the monomeric form of SARS-CoV-2 nsp10-nsp14 (E191A)-RNA complex |
Heteromer P0DTD1; | 5×ZN; 2×MG; | ||||
| Assess | ||||||
| Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 12/13 |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Structure of SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC |
Heteromer P0DTD1; | 8×ZN; 3×MG; 3×ADP; 3×1N7; 2×AF3; | ||||
| Assess | ||||||
| Architecture of a SARS-CoV-2 mini replication and transcription complex |
Heteromer P0DTD1; | 8×ZN; | ||||
| Assess | ||||||
| Architecture of a SARS-CoV-2 mini replication and transcription complex |
Heteromer P0DTD1; | 8×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 E-RTC complex with RNA-nsp9 and GMPPNP |
Heteromer P0DTD1; | 8×ZN; 1×GNP; 1×MG; | ||||
| Assess | ||||||
| A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors |
Heteromer P0DTD1; | 8×ZN; 1×GTP; | ||||
| Assess | ||||||
| A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors |
Heteromer P0DTD1; | 8×ZN; 1×GTP; | ||||
| Assess | ||||||
| A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors |
Heteromer P0DTD1; | 8×ZN; 1×GTP; | ||||
| Assess | ||||||
| Cryo-EM structure of an extended SARS-CoV-2 replication and transcription complex reveals an interm… |
Heteromer P0DTD1; | 8×ZN; 1×GDP; 1×MG; | ||||
| Assess | ||||||
| A mechanism for SARS-CoV-2 RNA capping and its inhibitor of AT-527 |
Heteromer P0DTD1; | 8×ZN; 1×GNP; | ||||
| Assess | ||||||
| A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors |
Heteromer P0DTD1; | 8×ZN; 1×GNP; 1×U5P; | ||||
| Assess | ||||||
| A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analogue inhibitors |
Heteromer P0DTD1; | 8×ZN; 2×MN; 1×U5P; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC (composite) |
Heteromer P0DTD1; | 8×ZN; 3×MG; 3×ADP; 3×1N7; 2×AF3; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(1)-RTC |
Heteromer P0DTD1; | 5×ZN; 2×MG; 2×ADP; 3×1N7; 1×AF3; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC - swiveled class |
Heteromer P0DTD1; | 8×ZN; 3×MG; 3×ADP; 2×AF3; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC dimer |
Heteromer P0DTD1; | 16×ZN; 6×MG; 6×ADP; 4×AF3; 2×1N7; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 backtracked complex bound to nsp13 helicase - nsp13(1)-BTC |
Heteromer P0DTD1; | 5×ZN; 2×MG; 2×ADP; 3×1N7; 1×AF3; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 backtracked complex complex bound to nsp13 helicase - nsp13(2)-BTC |
Heteromer P0DTD1; | 8×ZN; 3×MG; 3×ADP; 3×1N7; 2×AF3; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC - engaged class |
Heteromer P0DTD1; | 8×ZN; 3×MG; 3×ADP; 3×1N7; 2×AF3; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC - apo class |
Heteromer P0DTD1; | 8×ZN; 1×MG; 1×ADP; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to nsp13 helicase - nsp13(2)-RTC - open class |
Heteromer P0DTD1; | 8×ZN; 3×MG; 3×ADP; 3×1N7; 2×AF3; | ||||
| Assess | ||||||
| SARS-CoV-2 E-RTC complex with RNA-nsp9 |
Heteromer P0DTC1; P0DTD1; | 8×ZN; 2×MN; | ||||
| Assess | ||||||
| SARS-CoV-2 E-RTC bound with MMP-nsp9 and GMPPNP |
Heteromer P0DTC1; P0DTD1; | 8×ZN; 1×GNP; 1×6GS; | ||||
| Assess | ||||||
| SARS-CoV-2 RNA E-RTC complex with RMP-nsp9 and GMPPNP |
Heteromer P0DTC1; P0DTD1; | 8×ZN; 1×GNP; 1×MG; 1×F86; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 ExoN-nsp10 complex |
Heteromer P0DTD1; | 4×ZN; 23×EDO; 2×TLA; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-exoribonuclease domain |
Heteromer P0DTD1; | 4×ZN; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 ExoN-nsp10 complex containing Mg2+ ion |
Heteromer P0DTD1; | 4×ZN; 9×EDO; 1×CL; 1×MG; | ||||
| Assess | ||||||
| SARS-CoV-2 RNA-dependent RNA polymerase in complex with cofactors in reduced condition |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| SARS-Cov-2 RNA-dependent RNA polymerase in complex with cofactors |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Cryo-EM structure of the apo nsp12-nsp7-nsp8 complex |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 RNA-dependent RNA polymerase with gossypol binding |
Heteromer P0DTD1; | 2×GO3; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to CTP, in a pre-catalytic state |
Heteromer P0DTD1; | 2×ZN; 2×MG; 1×CTP; 1×L2B; | ||||
| Assess | ||||||
| SARS-CoV-2 RdRP catalytic complex with T33-1 RNA |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 RdRp with Molnupiravir/ NHC in the template strand base-paired with A |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| Dimeric form of SARS-CoV-2 RNA-dependent RNA polymerase |
Heteromer P0DTD1; | 4×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to ATP, in a pre-catalytic state |
Heteromer P0DTD1; | 1×ATP; 1×MG; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 RdRp with Molnupiravir/ NHC in the template strand base-paired with G |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 backtracked complex complex bound to nsp13 helicase - BTC (local refinement) |
Heteromer P0DTD1; | 2×ZN; 1×MG; 1×ADP; 3×1N7; | ||||
| Assess | ||||||
| Structure of replicating SARS-CoV-2 polymerase |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| Structure of elongating SARS-CoV-2 RNA-dependent RNA polymerase with Remdesivir at position -3 (str… |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to nsp9 and UMPCPP, as a pre-catalytic NMPylatio… |
Heteromer P0DTD1; | 2×ZN; 4×MG; 2×WSB; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to UTP, in a pre-catalytic state |
Heteromer P0DTD1; | 2×ZN; 1×MG; 1×UTP; | ||||
| Assess | ||||||
| Structure of elongating SARS-CoV-2 RNA-dependent RNA polymerase with Remdesivir at position -4 (str… |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| COVID-19 RNA-dependent RNA polymerase post-translocated catalytic complex |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| Structure of elongating SARS-CoV-2 RNA-dependent RNA polymerase with AMP at position -4 (structure … |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to GTP, in a pre-catalytic state |
Heteromer P0DTD1; | 2×ZN; 3×MG; 2×GTP; 1×L2B; | ||||
| Assess | ||||||
| COVID-19 RNA-dependent RNA polymerase pre-translocated catalytic complex |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to Remdesivir triphosphate, in a pre-catalytic s… |
Heteromer P0DTD1; | 1×NWX; 1×MG; 2×ZN; | ||||
| Assess | ||||||
| Structure of COVID-19 RNA-dependent RNA polymerase bound to ribavirin |
Heteromer P0DTD1; | 2×ZN; 3×MG; 2×POP; 1×RVP; | ||||
| Assess | ||||||
| Structure of the RNA-dependent RNA polymerase from SARS-CoV-2 |
Heteromer P0DTD1; | 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to RNA-nsp9, as a noncatalytic RNA-nsp9 binding … |
Heteromer P0DTD1; | 1×VSN; 1×MG; 2×ZN; | ||||
| Assess | ||||||
| Structure of COVID-19 RNA-dependent RNA polymerase (extended conformation) bound to penciclovir |
Heteromer P0DTD1; | 1×HCU; 4×MG; 2×ZN; 2×POP; | ||||
| Assess | ||||||
| The nsp12-nsp7-nsp8 complex bound to the template-primer RNA and triphosphate form of Remdesivir(RT… |
Heteromer P0DTD1; | 2×ZN; 1×POP; 2×MG; 1×F86; | ||||
| Assess | ||||||
| Structure of COVID-19 RNA-dependent RNA polymerase bound to penciclovir. |
Heteromer P0DTD1; | 2×ZN; 2×POP; 4×MG; 1×HCU; | ||||
| Assess | ||||||
| SARS-CoV-2 replication-transcription complex bound to RNA-nsp9 and GDP-betaS, as a pre-catalytic de… |
Heteromer P0DTD1; | 2×VSN; 2×ZN; 1×MG; | ||||
| Assess | ||||||
| Structure of COVID-19 RNA-dependent RNA polymerase bound to favipiravir |
Heteromer P0DTD1; | 1×1RP; 2×ZN; 2×POP; 4×MG; | ||||
| Assess | ||||||
| SARS-CoV-2 RdRp in complex with 4 Remdesivir monophosphate |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Structure of COVID-19 RNA-dependent RNA polymerase bound to suramin |
Heteromer P0DTD1; | 2×ZN; 2×H3U; | ||||
| Assess | ||||||
| Nsp7-Nsp8-Nsp12 SARS-CoV2 RNA-dependent RNA polymerase in complex with template:primer dsRNA and fa… |
Heteromer P0DTD1; | 2×ZN; 3×MG; 1×POP; 1×GE6; | ||||
| Assess | ||||||
| A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase |
Heteromer P0DTD1; | 2×ZN; 3×MG; 3×AT9; | ||||
| Assess | ||||||
| Cryo-EM structure of Favipiravir bound to replicating polymerase complex of SARS-CoV-2 in the pre-c… |
Heteromer P0DTD1; | 2×ZN; 1×MG; 1×GE6; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp12/7/8 complex with a native N-terminus nsp9 |
Heteromer P0DTD1; | 2×ZN; 1×MN; 1×POP; | ||||
| Assess | ||||||
| SARS-CoV-2 RdRp/RNA complex |
Heteromer P0DTD1; | 2×ZN; 1×MG; | ||||
| Assess | ||||||
| Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 10/11 |
Heteromer P0DTD1; | 2×GOL; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp10/11 (P6-P1) |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 9/10 |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| SARS-CoV-2 Mpro mutant (H41A) in complex with nsp9|10 peptidyl substrate |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 8/9 |
Heteromer P0DTD1; | 2×GOL; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease in complex with nsp8/9 substrate peptide |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp8/9 (P6-P1) |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 7/8 |
Heteromer P0DTD1; | 12×EDO; 2×GOL; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp7/8 (P6-P1) |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| SARS-CoV-2 Mpro mutant (H41A) in complex with nsp6|7 peptidyl substrate |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp6/7 (P6-P1) |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| SARS-CoV-2 endoribonuclease Nsp15 bound to dsRNA |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with a Lys48-… |
Heteromer P0CG47; P0DTD1; | 1×ZN; 2×CL; 2×EDO; | ||||
| Assess | ||||||
| SARS CoV-2 PLpro in complex with ISG15 C-terminal domain propargylamide |
Heteromer P05161; P0DTD1; | 3×GOL; 1×ZN; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2, C111S/D286N mutant, in complex with a … |
Heteromer P0CG47; P0CG48; P0DTD1; | 1×ZN; 4×EDO; | ||||
| Assess | ||||||
| SARS-CoV-2 Mpro mutant (H41A) in complex with nsp4|5 peptidyl substrate |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Room-temperature X-ray structure of SARS-CoV-2 main protease C145A mutant in complex with substrate… |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Structure of SARS CoV-2 main protease shows simultaneous processing of its N- and C-terminii |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with human IS… |
Heteromer P05161; P0DTD1; | 1×ZN; | ||||
| Assess | ||||||
| Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 5/6 |
Heteromer P0DTD1; | 9×GOL; 1×DMS; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp4/5 (P6-P1) |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 4/5 |
Heteromer P0DTD1; | 18×GOL; 14×DMS; | ||||
| Assess | ||||||
| SARS-CoV-2 Main protease C145S mutant in complex with N and C-terminal residues |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| SARS-CoV-2 main protease in complex with N-terminal autoprocessing substrate |
Heteromer P0DTD1; | 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Mpro mutant (H41A) in complex with nsp5|6 peptidyl substrate |
Heteromer P0DTD1; | 2×DMS; | ||||
| Assess | ||||||
| SARS CoV-2 PLpro in complex with ubiquitin propargylamide |
Heteromer P0CG47; P0DTD1; | 1×ZN; | ||||
| Assess | ||||||
| PLpro-C111S with mISG15 |
Heteromer P0DTD1; Q64339; | 1×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Mpro Double Mutant (H41A and T21I) in complex with nsp4/5 peptidyl substrate |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) C145A in Complex with Cleavage Site Nsp5/6 (P6-P1) |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| SARS-CoV2 3C-Like protease complexed with Nemo peptide |
Heteromer P0DTD1; Q9Y6K9; | |||||
| Assess | ||||||
| SARS-CoV-2 polyprotein substrate regulates the stepwise Mpro cleavage reaction |
Heteromer P0DTC1; P0DTD1; | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (Mpro) C145A mutant in complex with peptide from huma… |
Heteromer P0DTD1; Q9NXH9; | 1×CL; 2×NA; 3×GOL; | ||||
| Assess | ||||||
| the complex of SARS-CoV2 3CL and NB1A2 |
Heteromer P0DTD1; | 1×SO4; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 5 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H28; 2×GOL; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 7 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H3D; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 4 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H3E; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 8 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H29; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 2 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H3B; 3×GOL; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 2 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H3C; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 6 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H3A; 2×GOL; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 1 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×MTA; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 10 |
Heteromer P0DTC1; P0DTD1; | 1×A1H4B; 1×MES; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 9 |
Heteromer P0DTC1; P0DTD1; | 1×A1H4C; 1×MES; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 nsp16-nsp10 in complex with SAM derivative inhibitor 11 |
Heteromer P0DTC1; P0DTD1; | 1×MES; 1×A1H4D; 2×ZN; | ||||
| Assess | ||||||
| the complex of SARS-CoV2 3cl and NB2B4 |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| The 1.95 A Crystal Structure of the Co-factor Complex of NSP7 and the C-terminal Domain of NSP8 fro… |
Heteromer P0DTD1; | 3×EDO; | ||||
| Assess | ||||||
| The 1.5 A Crystal Structure of the Co-factor Complex of NSP7 and the C-terminal Domain of NSP8 from… |
Heteromer P0DTD1; | 5×EDO; | ||||
| Assess | ||||||
| Crystal Structure of the Second Form of the Co-factor Complex of NSP7 and the C-terminal Domain of … |
Heteromer P0DTD1; | 2×ACY; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 NSP7-NSP8 complex. |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Crystal structure of the nsp7-nsp8 complex of SARS-CoV-2 |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Crystal structure of 2019-nCoV nsp7-nsp8c complex |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Crystal structure of the co-factor complex of NSP7 and the C-terminal domain of NSP8 from SARS CoV-2 |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Nonstructural protein 7 and 8 complex of SARS-CoV-2 |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 nucleocapsid protein N-terminal domain in complex with Ubl1 |
Heteromer P0DTC9; P0DTD1; | |||||
| Assess | ||||||
| Structure of SARS-CoV-2 nucleoprotein in dynamic complex with its viral partner nsp3a |
Heteromer P0DTC9; P0DTD1; | |||||
| Assess | ||||||
| Nanobody bound SARS-CoV-2 Nsp9 |
Heteromer P0DTD1; | |||||
| Assess | ||||||
| SARS-CoV-2 Nsp1 and rabbit 40S ribosome complex |
Heteromer A0A5K1UJS7; B7NZS8; G1SFR8; G1SGX4; G1SIZ2; G1SJB4; G1SS70; G1SVB0; G1SZ47; G1T1F0; G1T3D8; G1T8A2; G1TDB3; G1TFE8; G1TFM5; G1TG89; G1TIB4; G1TJW1; G1TK17; G1TLT8; G1TN62; G1TNM3; G1TPG3; G1TPV3; G1TRM4; G1TU13; G1TZ76; G1U0Q2; P0DTD1; P15880; P62277; P62979; P63220; | |||||
| Assess | ||||||
| SARS-CoV-2 Nsp1, CrPV IRES and rabbit 40S ribosome complex |
Heteromer A0A5K1UJS7; B7NZS8; G1SFR8; G1SGX4; G1SIZ2; G1SJB4; G1SS70; G1SVB0; G1SZ47; G1T1F0; G1T3D8; G1T8A2; G1TDB3; G1TFE8; G1TFM5; G1TG89; G1TIB4; G1TJW1; G1TK17; G1TLT8; G1TN62; G1TNM3; G1TPG3; G1TPV3; G1TRM4; G1TU13; G1TZ76; G1U0Q2; P0DTD1; P15880; P62277; P62979; P63220; | |||||
| Assess | ||||||
| SARS-CoV-2-Nsp1-40S complex, composite map |
Heteromer P08708; P08865; P0DTD1; P15880; P23396; P25398; P39019; P42677; P46781; P46782; P46783; P60866; P61247; P62081; P62241; P62244; P62249; P62263; P62266; P62269; P62273; P62277; P62280; P62701; P62753; P62841; P62847; P62851; P62854; P62857; P62861; P62945; P62979; P63220; P63244; | 166×MG; 3×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2-Nsp1-40S complex, focused on body |
Heteromer P08708; P08865; P0DTD1; P15880; P42677; P46781; P61247; P62081; P62241; P62244; P62263; P62266; P62277; P62280; P62701; P62753; P62847; P62854; P62861; P62945; P63220; | 109×MG; 1×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Nsp1 bound to a human 43S preinitiation ribosome complex - state 2 |
Heteromer O00303; O15371; O15372; P05198; P08708; P08865; P0DTD1; P15880; P20042; P23396; P25398; P39019; P41091; P41567; P42677; P46781; P46782; P46783; P47813; P55884; P60228; P60866; P61247; P62081; P62241; P62244; P62249; P62263; P62266; P62269; P62273; P62277; P62280; P62701; P62753; P62841; P62847; P62851; P62854; P62857; P62861; P62945; P62979; P63220; P63244; Q13347; Q14152; Q7L2H7; Q99613; Q9UBQ5; Q9Y262; | 4×ZN; 1×GTP; 1×MG; | ||||
| Assess | ||||||
| SARS-CoV-2 Nsp1 bound to the human 40S ribosomal subunit |
Heteromer P08708; P08865; P0DTD1; P15880; P23396; P25398; P39019; P42677; P46781; P46782; P46783; P60866; P61247; P62081; P62241; P62244; P62249; P62263; P62266; P62269; P62273; P62277; P62280; P62701; P62753; P62841; P62847; P62851; P62854; P62857; P62861; P62945; P62979; P63220; P63244; | 3×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Nsp1 bound to a human 43S preinitiation ribosome complex - state 1 |
Heteromer O00303; O15371; O15372; P08708; P08865; P0DTD1; P15880; P23396; P25398; P39019; P42677; P46781; P46782; P46783; P55884; P60228; P60866; P61247; P62081; P62241; P62244; P62249; P62263; P62266; P62269; P62273; P62277; P62280; P62701; P62753; P62841; P62847; P62851; P62854; P62857; P62861; P62945; P62979; P63220; P63244; Q13347; Q14152; Q7L2H7; Q99613; Q9UBQ5; Q9Y262; | 3×ZN; | ||||
| Assess | ||||||
| SARS-COV-2 nsp1 in complex with human 40S ribosome |
Heteromer P08708; P08865; P0DTD1; P15880; P23396; P25398; P39019; P42677; P46781; P46782; P46783; P60866; P61247; P62081; P62241; P62244; P62249; P62263; P62266; P62269; P62273; P62277; P62280; P62701; P62753; P62841; P62847; P62851; P62854; P62857; P62861; P62945; P62979; P63220; P63244; | 1×MG; 3×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Nsp1 bound to a pre-40S-like ribosome complex - state 2 |
Heteromer P08708; P08865; P0DTD1; P15880; P23396; P25398; P39019; P42677; P46781; P46782; P46783; P60866; P61247; P62081; P62241; P62244; P62249; P62263; P62266; P62269; P62273; P62277; P62280; P62701; P62753; P62841; P62847; P62851; P62854; P62857; P62861; P62979; P63220; P63244; Q2NL82; | 3×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Nsp1 bound to a pre-40S-like ribosome complex |
Heteromer P08708; P08865; P0DTD1; P15880; P23396; P25398; P39019; P42677; P46781; P46782; P46783; P60866; P61247; P62081; P62241; P62244; P62249; P62263; P62266; P62269; P62273; P62277; P62280; P62701; P62753; P62841; P62847; P62851; P62857; P62861; P62979; P63220; P63244; Q2NL82; | 2×ZN; | ||||
| Assess | ||||||
| Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 nsp14 peptide (orf1ab)6420-6434 |
Heteromer D7RIG0; P01903; P0DTD1; | 16×EDO; 4×SO4; | ||||
| Assess | ||||||
| Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 nsp3 epitope (orf1ab)1350-1364 |
Heteromer D7RIG0; P01903; P0DTD1; | 1×EDO; 1×SIN; | ||||
| Assess | ||||||
| Human leukocyte antigen B*07:02 in complex with SARS-CoV2 epitope IPRRNVATL |
Heteromer P01889; P0DTD1; P61769; | |||||
| Assess | ||||||
| Human leukocyte antigen A*0201 in complex with SARS-CoV2 epitope KLWAQCVQL |
Heteromer A0A140T913; P0DTD1; P61769; | 2×GOL; | ||||
| Assess | ||||||
| Human leukocyte antigen A*0201 in complex with SARS-CoV2 epitope ALWEIQQVV |
Heteromer A0A140T913; P0DTD1; P61769; | 3×GOL; 2×PGE; | ||||
| Assess | ||||||
| TRIM7 in complex with C-terminal peptide of NSP5 |
Heteromer P0DTD1; Q9C029; | |||||
| Assess | ||||||
| TRIM7 in complex with C-terminal peptide of NSP12 |
Heteromer P0DTD1; Q9C029; | |||||
| Assess | ||||||
| TRIM7 in complex with C-terminal peptide of NSP8 |
Heteromer P0DTD1; Q9C029; | |||||
| Assess | ||||||
| PanDDA analysis group deposition of ground-state model of SARS-CoV-2 NendoU | homo-6-mer | 6×CIT; | ||||
| Assess | ||||||
| Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with Uridine-5'-Monophos… | homo-6-mer | 6×U5P; 6×TRS; 30×EDO; 12×ACT; 3×SO4; 6×FMT; | ||||
| Assess | ||||||
| Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with potential repurposi… | homo-6-mer | 6×CMU; 6×PO4; 27×EDO; 12×FMT; | ||||
| Assess | ||||||
| Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with 3'-uridinemonophosp… | homo-6-mer | 6×U3P; 60×EDO; 3×NA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with EN300-16… | homo-6-mer | 3×ZQG; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 NendoU in complex with Z2443429438 | homo-6-mer | 6×CIT; 21×WNM; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z2697514… | homo-6-mer | 3×GWG; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with FUZS-5 | homo-6-mer | 6×CIT; 6×WUV; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z4254496… | homo-6-mer | 3×EJW; | ||||
| Assess | ||||||
| Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with the Product Nucleot… | homo-6-mer | 6×PO4; 9×EDO; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 NendoU in complex with Z2472938267 | homo-6-mer | 3×S6V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z1424343… | homo-6-mer | 3×ZQM; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z59181945 | homo-6-mer | 6×CIT; 3×VWG; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z2391367… | homo-6-mer | 3×K3A; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 NendoU in complex with LIZA-7 | homo-6-mer | 6×0MI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z1530301… | homo-6-mer | 6×CIT; 3×ZQA; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 NendoU in complex with Z18197050 | homo-6-mer | 6×RZG; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with EN300-32… | homo-6-mer | 6×CIT; 6×WOY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z3219959… | homo-6-mer | 6×CIT; 6×W3G; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with EN300-10… | homo-6-mer | 6×ZQJ; | ||||
| Assess | ||||||
| Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2. | homo-6-mer | 27×GOL; 3×MG; 9×ACY; 3×CL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z1673618… | homo-6-mer | 3×WL7; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z3198912… | homo-6-mer | 6×CIT; 6×ZQD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with PB225518… | homo-6-mer | 6×CIT; 6×WUM; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z68299550 | homo-6-mer | 6×JOV; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z56900771 | homo-6-mer | 6×CIT; 6×WUJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z2889976… | homo-6-mer | 6×CIT; 6×WUG; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with EN300-18… | homo-6-mer | 6×CIT; 3×WUS; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 NendoU in complex with CSC000178569 | homo-6-mer | 3×0OI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z31504642 | homo-6-mer | 6×CIT; 3×WJD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with BBL029427 | homo-6-mer | 6×CIT; 3×WUY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NendoU in complex with Z2856434… | homo-6-mer | 6×O3G; | ||||
| Assess | ||||||
| Crystal structure from SARS-CoV-2 NendoU NSP15 | homo-6-mer | 6×B3P; 6×SO4; | ||||
| Assess | ||||||
| Room temperature structure of NSP15 Endoribonuclease from SARS CoV-2 solved using SFX. | homo-6-mer | 6×CIT; | ||||
| Assess | ||||||
| Crystal structure from SARS-CoV-2 NendoU NSP15 | homo-6-mer | 6×CIT; | ||||
| Assess | ||||||
| Crystal structure from SARS-COV2 NendoU NSP15 | homo-6-mer | 6×PO4; | ||||
| Assess | ||||||
| Crystal Structure of SARS CoV-2 NSP15 Endroribonuclease H250A | homo-6-mer | |||||
| Assess | ||||||
| The 1.9 A Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with a Citrate | homo-6-mer | 66×EDO; 9×PEG; 6×CIT; | ||||
| Assess | ||||||
| Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with Uridine-2',3'-Vanad… | homo-6-mer | 6×UVC; 6×ACT; 3×EDO; 6×SO4; | ||||
| Assess | ||||||
| Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2 in the Complex with Uridine-3',5'-Dipho… | homo-6-mer | 6×VQV; 6×EDO; | ||||
| Assess | ||||||
| SARS-CoV-2 endoribonuclease Nsp15 bound to dsRNA | homo-6-mer | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 NSP15 NendoU at pH 6.0 | homo-6-mer | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 NSP15 NendoU at pH 7.5 | homo-6-mer | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 NSP15 NendoU in BIS-Tris pH 6.0 | homo-6-mer | |||||
| Assess | ||||||
| SARS-CoV-2 Nsp15 endoribonuclease post-cleavage state | homo-6-mer | |||||
| Assess | ||||||
| Nucleotide bound SARS-CoV-2 Nsp15 | homo-6-mer | 6×U5P; 6×PO4; | ||||
| Assess | ||||||
| SARS-CoV-2 Nsp15 endoribonuclease pre-cleavage state | homo-6-mer | |||||
| Assess | ||||||
| FR6-bound SARS-CoV-2 Nsp9 RNA-replicase | homo-6-mer | 6×SO4; 12×X0Y; 2×MLI; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 PLpro C111S mutant | homo-4-mer | 4×ZN; 1×EDO; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Main protease C145S in complex with N-terminal peptide | homo-4-mer | |||||
| Assess | ||||||
| Cryo-EM structure of SARS-CoV-2 Main protease C145S in complex with N-terminal peptide | homo-4-mer | |||||
| Assess | ||||||
| THE CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE apo form at 2.2 angstrom | homo-4-mer | |||||
| Assess | ||||||
| Crystal Structure of NendoU (Uridylate-specific endoribonuclease, nsp15) from Betacoronavirus SARS-… | homo-3-mer | 3×TRS; 6×CL; | ||||
| Assess | ||||||
| Crystal Structure of NendoU (Uridylate-specific endoribonuclease, nsp15) from Betacoronavirus SARS-… | homo-3-mer | 3×ACT; 3×CIT; 6×FMT; | ||||
| Assess | ||||||
| The crystal structure of papain-like protease of SARS CoV-2 | homo-3-mer | 4×ZN; 3×CL; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 helicase APO form | homo-2-mer | 6×ZN; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 papain-like protease (PLPro) C112S mutant bound to compound S43 | homo-2-mer | 2×ZN; 2×GYX; | ||||
| Assess | ||||||
| Crystal structures of SARS-CoV-2 papain-like protease in complex with covalent inhibitors | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) at 1.2 A Resolution and a Possible Capt… | homo-2-mer | 22×DMS; 2×ZN; | ||||
| Assess | ||||||
| THE 1.28A CRYSTAL STRUCTURE OF 3CL MAINPRO OF SARS-COV-2 WITH OXIDIZED C145 (sulfinic acid cysteine) | homo-2-mer | 4×EDO; 8×FMT; 2×ACT; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Tegafur | homo-2-mer | 2×S7W; 8×DMS; | ||||
| Assess | ||||||
| Crystal structure of F2F-2020198-00X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2. | homo-2-mer | 2×83W; 2×CL; 3×NA; 1×MPD; 1×EDO; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) in Complex with Covalent Inhibitor Boce… | homo-2-mer | 2×U5G; 10×DMS; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to UNC-2327 | homo-2-mer | 2×CL; 6×DMS; 2×RV5; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML102 | homo-2-mer | 2×91I; 2×CA; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI5 | homo-2-mer | 2×VHM; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Pelitinib | homo-2-mer | 8×DMS; 2×93J; 2×IMD; | ||||
| Assess | ||||||
| X-ray Structure of SARS-CoV-2 main protease bound to Boceprevir at 1.45 A | homo-2-mer | 2×U5G; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 16×DMS; 1×CL; 2×RZU; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease in mature form | homo-2-mer | |||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Climbazole | homo-2-mer | 10×DMS; 2×IMD; 2×RQH; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-15 | homo-2-mer | 25×DMS; 2×NT9; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 1×CL; 2×S7U; | ||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease in H41A mutation | homo-2-mer | |||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of F2F-2020185-01X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2. | homo-2-mer | 2×83N; 1×EDO; 2×FMT; 2×NA; 2×CL; 1×MPD; | ||||
| Assess | ||||||
| Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 240 K | homo-2-mer | 14×DMS; 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) at 240 K | homo-2-mer | 14×DMS; 2×ZN; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 18×DMS; 3×CL; 2×S5L; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 2×OYF; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-21 | homo-2-mer | 9×DMS; 2×CL; 1×XZO; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-3 | homo-2-mer | 2×Y2C; 4×DMS; 1×NA; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 19×DMS; 2×CL; 2×S4X; 1×NA; | ||||
| Assess | ||||||
| Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 100 K | homo-2-mer | 10×DMS; 2×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Isofloxythepin | homo-2-mer | 4×S8T; 6×DMS; 2×IMD; 2×PEG; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) at 100 K | homo-2-mer | 10×DMS; 2×ZN; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-20 | homo-2-mer | 12×DMS; 2×NA; 2×CL; 1×XZT; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-11 | homo-2-mer | 1×Y3N; 14×DMS; 2×NA; 2×CL; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) A193P Mutant in Complex with Inhibitor Nirmatr… | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×S7C; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332 | homo-2-mer | 2×4WI; 2×DMS; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI1 | homo-2-mer | 2×GHX; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI19 | homo-2-mer | 2×81L; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to AZD6482. | homo-2-mer | 2×A82; 4×CL; 8×DMS; 6×PEG; 2×CA; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to RS102895 | homo-2-mer | 2×R6Q; 2×IMD; 12×DMS; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in its apo-form | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of the main protease (3CLpro/Mpro) of SARS-CoV-2 at 1.6A resolution (spacegroup P… | homo-2-mer | 14×EDO; 1×CL; 1×NA; | ||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease in complex with carmofur | homo-2-mer | 2×JRY; 10×DMS; | ||||
| Assess | ||||||
| Crystal structure of 3C-like protease from SARS-CoV-2 in complex with covalent inhibitor | homo-2-mer | 5×NI; 2×CL; 2×BOV; | ||||
| Assess | ||||||
| Mpro inhibitors of SARS-CoV-2 | homo-2-mer | |||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×S6K; | ||||
| Assess | ||||||
| Structure of Mpro from SARS-CoV-2 in complex with FGA147 | homo-2-mer | 2×QH0; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor | homo-2-mer | 2×4W8; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 2×QG3; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI12 | homo-2-mer | 2×7VB; 2×DMS; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) variant Y54F at 1.63 A resolution | homo-2-mer | 8×DMS; 2×GOL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Tretazicar. | homo-2-mer | 2×CB1; 10×DMS; 4×CL; | ||||
| Assess | ||||||
| Crystal structure of F2F-2020184-00X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2. | homo-2-mer | 2×83F; 4×ACT; 5×EDO; 5×FMT; 3×NA; 2×CL; 1×DMS; 1×MPD; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI12 | homo-2-mer | 2×7VB; 2×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×KG9; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI3 | homo-2-mer | 2×VHV; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Clonidine | homo-2-mer | 2×CLU; 14×DMS; | ||||
| Assess | ||||||
| Crystal structure of Mpro with inhibitor r1 | homo-2-mer | 2×VJA; 2×DMS; | ||||
| Assess | ||||||
| Crystal structure of ligand-free SARS-CoV-2 main protease | homo-2-mer | |||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Tofogliflozin. | homo-2-mer | 2×RT2; 10×DMS; 4×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to AR-42. | homo-2-mer | 10×DMS; 2×QCP; | ||||
| Assess | ||||||
| Crystal structure of the main protease (3CLpro/Mpro) of SARS-CoV-2 at 1.65A resolution (spacegroup … | homo-2-mer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI4 | homo-2-mer | 2×VHJ; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI7 | homo-2-mer | 2×XM2; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (Mpro) Mutant (T21I) in complex with protease inhibit… | homo-2-mer | 2×4WI; 2×LQZ; | ||||
| Assess | ||||||
| Crystal structure of X77 bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 in spacegroup P2(1)… | homo-2-mer | 2×X77; 5×EDO; 2×CL; 1×DMS; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-1 | homo-2-mer | 1×XWH; 10×DMS; 2×NA; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 14×DMS; 1×CL; 2×S3X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 20×DMS; 2×PJX; 3×CL; | ||||
| Assess | ||||||
| Crystal structure of F2F-2020209-00X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2. | homo-2-mer | 2×90I; 2×CL; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-13 | homo-2-mer | 7×DMS; 1×Y0S; 2×NA; 1×CL; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) Double Mutant (L50F and E166V) in Complex with… | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with MG132 | homo-2-mer | 2×DMS; 2×ALD; 3×GOL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-8 | homo-2-mer | 1×Y1C; 8×DMS; 1×CL; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×S1U; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 2×Q99; 1×CL; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) G15S Mutant in Complex with Inhibitor nirmatre… | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 2×QD4; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML1000 | homo-2-mer | 2×I70; 2×CL; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI38 | homo-2-mer | 2×I68; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor UAW248 | homo-2-mer | 2×GOL; 1×NA; 1×DMS; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Ipidacrine. | homo-2-mer | 4×DMS; 2×CL; 2×R9W; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) in Complex with Covalent Inhibitor VBY-… | homo-2-mer | 2×ZL7; 16×DMS; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 3CL protease in complex with inhibitor 18 | homo-2-mer | |||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Ifenprodil | homo-2-mer | 2×QEL; 4×DMS; 4×IMD; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Mpro in complex with the activity-based probe, biotin-PEG(4)-Abu-Tl… | homo-2-mer | 2×Q5T; 4×CL; 2×NA; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Adrafinil. | homo-2-mer | 8×DMS; 2×RNW; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 14×DMS; 2×OYX; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 18×DMS; 1×CL; 2×S0X; | ||||
| Assess | ||||||
| Crystal structure of F2F-2020216-01X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2. | homo-2-mer | 2×90X; 2×SO4; 1×EDO; 2×CL; 2×NO3; 1×NA; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with an inhibitor TKB-272 | homo-2-mer | 2×WOK; 2×PEG; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×QD9; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in complex with Telaprevir | homo-2-mer | 2×SV6; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-24 | homo-2-mer | 10×DMS; 1×GT7; 1×CL; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 Main Protease | homo-2-mer | 1×NA; 2×FMT; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with 7-O-methyl-myricetin | homo-2-mer | 2×HER; 1×GOL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 4×DMS; 1×QOO; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 15 | homo-2-mer | 2×YTM; | ||||
| Assess | ||||||
| crystal structures of diastereomer (R,S,S)-13b (13b-H) in complex with the SARS-CoV-2 Mpro. | homo-2-mer | 2×V9R; 4×DMS; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of the free enzyme of the SARS-CoV-2 (2019-nCoV) main protease | homo-2-mer | |||||
| Assess | ||||||
| Reduced form of SARS-CoV-2 Main Protease determined by XFEL radiation | homo-2-mer | 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Main protease C145S mutant | homo-2-mer | |||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 2×CL; 2×KFU; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-25 | homo-2-mer | 1×5F8; 9×DMS; 1×NA; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to MUT056399. | homo-2-mer | 2×RQN; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease (Mpro) complex with AC1115 | homo-2-mer | 2×W28; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) in Complex with Covalent Inhibitor Narl… | homo-2-mer | 2×NNA; 8×DMS; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of Mpro in complex with inhibitor CDD-1713 | homo-2-mer | 2×YCV; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 2×QM9; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) L167F Mutant in Complex with Inhibitor Nirmatr… | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Room temperature X-ray crystallography reveals catalytic cysteine in the SARS-CoV-2 3CL Mpro is hig… | homo-2-mer | 2×NEN; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (3CL Mpro) in complex with BBH-2 | homo-2-mer | 2×I1Z; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI42 | homo-2-mer | 2×8I7; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Mpro with compound C5 | homo-2-mer | 2×P5X; | ||||
| Assess | ||||||
| The crystal structure of 3CL MainPro of SARS-CoV-2 with oxidized Cys145 (Sulfenic acid cysteine). | homo-2-mer | 2×EDO; 1×CL; | ||||
| Assess | ||||||
| SARS-COV2 NSP5 in the presence of Zn2+ | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML2006a | homo-2-mer | 2×X6O; | ||||
| Assess | ||||||
| Crystal structure of MG-132 covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 in sp… | homo-2-mer | 1×CL; 2×ALD; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to 2-Methyl-1-tetralone. | homo-2-mer | 2×P6N; 2×DMS; 2×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to SEN1269 ligand | homo-2-mer | 2×CL; 1×S1W; | ||||
| Assess | ||||||
| Room temperature X-ray crystallography reveals catalytic cysteine in the SARS-CoV-2 3CL Mpro is hig… | homo-2-mer | 2×DMS; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to pyrithione zinc | homo-2-mer | 2×PK8; 2×IMD; 2×DMS; 2×CL; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 26 | homo-2-mer | 2×XFD; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI13 | homo-2-mer | 2×7VI; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI30 | homo-2-mer | 2×I70; | ||||
| Assess | ||||||
| Room-temperature X-ray structure of SARS-CoV-2 main protease (3CL Mpro) in complex with a non-coval… | homo-2-mer | 2×YD1; | ||||
| Assess | ||||||
| Structure of wild-type substrate free SARS-CoV-2 Mpro. | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML1006a | homo-2-mer | 2×M0C; 2×CL; | ||||
| Assess | ||||||
| Room temperature X-ray crystallography reveals oxidation and reactivity of cysteine residues in SAR… | homo-2-mer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 5 | homo-2-mer | 2×XF1; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI88 | homo-2-mer | 2×GJ3; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (3CL Mpro) in complex with NBH-2 | homo-2-mer | 2×NB2; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound 10 | homo-2-mer | 2×OZB; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-17 | homo-2-mer | 9×DMS; 1×CL; 1×Y0H; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 17×DMS; 1×CL; 2×RZU; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CLpro in complex with the non-covalent inhibitor WU-04 | homo-2-mer | 2×J7R; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with compound 4 in space group P1 | homo-2-mer | 2×TG3; 1×BTB; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease N142S mutant in complex with Nirmatrelvir | homo-2-mer | 2×4WI; 2×DMS; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML1001 | homo-2-mer | 2×8ZI; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI23 | homo-2-mer | 2×7YB; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI8 | homo-2-mer | 2×NOL; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI48 | homo-2-mer | 2×8T6; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI86 | homo-2-mer | 2×9HA; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with halicin | homo-2-mer | 6×U88; | ||||
| Assess | ||||||
| Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubili… | homo-2-mer | 2×XTP; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI37 | homo-2-mer | 2×WGI; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI49 | homo-2-mer | 2×8UI; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI19 | homo-2-mer | 2×81L; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI24 | homo-2-mer | 2×7YI; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML2006a2 | homo-2-mer | 2×X70; 2×CL; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI33 | homo-2-mer | 2×I71; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MI-09 | homo-2-mer | 2×I80; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI32 | homo-2-mer | 2×8GW; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI37 | homo-2-mer | 2×I69; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in its apo-form | homo-2-mer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI33 | homo-2-mer | 2×I71; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI85 | homo-2-mer | 2×I65; | ||||
| Assess | ||||||
| Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication | homo-2-mer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI35 | homo-2-mer | 2×8H9; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI87 | homo-2-mer | 2×9GI; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI27 | homo-2-mer | 2×7YZ; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-69 | homo-2-mer | 2×H69; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI25 | homo-2-mer | 2×7YQ; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound JZD-26 | homo-2-mer | 2×K9U; | ||||
| Assess | ||||||
| Structure of the apo form of Mpro from SARS-CoV-2 | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease M49I mutant in complex with Nirmatrelvir | homo-2-mer | 2×4WI; 3×DMS; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-4 | homo-2-mer | 18×DMS; 2×Y25; 1×NA; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) at 298 K | homo-2-mer | 4×DMS; 2×ZN; | ||||
| Assess | ||||||
| Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 298 K | homo-2-mer | 4×DMS; 2×ZN; | ||||
| Assess | ||||||
| Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors | homo-2-mer | 2×A1W; | ||||
| Assess | ||||||
| The co-crystal structure of SARS-CoV-2 main protease with peptidomimetic inhibitor N-((S)-3-methyl-… | homo-2-mer | 2×H6L; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound Z199538122 | homo-2-mer | 2×T4V; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CLpro in complex with the non-covalent inhibitor WU-02 | homo-2-mer | 2×J7O; | ||||
| Assess | ||||||
| Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Telaprevir | homo-2-mer | 2×SV6; | ||||
| Assess | ||||||
| Ambient-Temperature Serial Femtosecond X-ray Crystal structure of SARS-CoV-2 Main Protease at 1.9 A… | homo-2-mer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI26 | homo-2-mer | 2×7YW; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound Z2799209083 | homo-2-mer | 2×SRU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×QGO; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI8 | homo-2-mer | 2×NOL; | ||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI14 | homo-2-mer | 2×7VQ; | ||||
| Assess | ||||||
| Crystal Structure of Sars-Cov-2 Mpro at 1.90 A resolution-1 | homo-2-mer | |||||
| Assess | ||||||
| Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication | homo-2-mer | 2×K36; | ||||
| Assess | ||||||
| Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors | homo-2-mer | 2×U1J; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 1.90 A resolution-7 | homo-2-mer | |||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound Z1530718726 | homo-2-mer | 2×Z26; | ||||
| Assess | ||||||
| Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubili… | homo-2-mer | 2×XTJ; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI60 | homo-2-mer | 2×WGE; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 1.93 A resolution-5 | homo-2-mer | |||||
| Assess | ||||||
| Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubili… | homo-2-mer | 2×XU4; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (Mpro) Mutant (E166V) in complex with protease inhibi… | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Crystal structure of SARS Cov-2 main protease in complex with an inhibitor 58 | homo-2-mer | 8×DMS; 2×OCA; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with compound 4 | homo-2-mer | 2×TG3; | ||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML104 | homo-2-mer | 2×91Z; 2×CL; 2×CA; | ||||
| Assess | ||||||
| Acyl-enzyme intermediate structure of SARS-CoV-2 Mpro in complex with its C-terminal autoprocessing… | homo-2-mer | 3×DMS; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Glutathione isopropyl ester | homo-2-mer | 2×S8H; 4×DMS; 2×IMD; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML3006a | homo-2-mer | 2×X9Z; 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML4006a | homo-2-mer | 2×XA8; 2×CL; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI11 | homo-2-mer | 2×7V2; | ||||
| Assess | ||||||
| Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubili… | homo-2-mer | 2×XTM; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 2×QMX; | ||||
| Assess | ||||||
| Crystal Structure of Apo/Unliganded SARS-CoV-2 Main Protease (Mpro) at 310 K | homo-2-mer | 4×DMS; 2×ZN; | ||||
| Assess | ||||||
| Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 310 K | homo-2-mer | 4×DMS; 2×ZN; | ||||
| Assess | ||||||
| The co-crystal structure of SARS-CoV-2 main protease with peptidomimetic inhibitor N-((S)-3-methyl-… | homo-2-mer | 2×H6F; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-45 | homo-2-mer | 2×5ZW; | ||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease in apo form | homo-2-mer | |||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with PF-07321332 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-70 | homo-2-mer | 2×5ZN; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor PF-07321332 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Crystal structure of main protease of SARS-CoV-2 complexed with inhibitor | homo-2-mer | 2×Y8O; | ||||
| Assess | ||||||
| Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubili… | homo-2-mer | 2×XV4; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML2006a4 | homo-2-mer | 2×X6T; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound Z1530724963 | homo-2-mer | 2×87H; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound Z1530724813 | homo-2-mer | 2×860; | ||||
| Assess | ||||||
| Room-temperature X-ray structure of SARS-CoV-2 main protease in complex with GC-376 | homo-2-mer | 2×K36; | ||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 2.0 A resolution -9 | homo-2-mer | |||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with Mcule-CSR-49419… | homo-2-mer | 2×5YJ; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Mpro with compound C2 | homo-2-mer | 2×P7L; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-52 | homo-2-mer | 2×5Z3; | ||||
| Assess | ||||||
| Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication | homo-2-mer | 2×UED; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-78 | homo-2-mer | 2×5Z7; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease S144A (Mpro S144A) in Complex with ML1006a | homo-2-mer | 2×M0C; 2×CL; | ||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with its C-terminal autoprocessing seq… | homo-2-mer | |||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease in complex with compound ZZ4461624291 | homo-2-mer | 2×SVL; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-68 | homo-2-mer | 2×5YN; | ||||
| Assess | ||||||
| SARS-CoV2 NSP5 in complex with a GC-376 based peptidomimetic PROTAC | homo-2-mer | 2×VQN; | ||||
| Assess | ||||||
| Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 298 K at high humidity | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) at 298 K and High Humidity | homo-2-mer | 2×ZN; | ||||
| Assess | ||||||
| The co-crystal structure of SARS-CoV-2 main protease with (S)-2-cinnamamido-N-((S)-1-oxo-3-((S)-2-o… | homo-2-mer | 2×H63; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 Omicron main protease (Mpro) in complex with inhibitor GC376 | homo-2-mer | 2×K36; 4×PEG; | ||||
| Assess | ||||||
| Complex Structure of SARS-CoV-2 3CL Protease with TG-0205221 | homo-2-mer | 2×NOL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease E166V mutant in complex with an inhibitor TKB-272 | homo-2-mer | 2×WOK; 2×PEG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to LSN2463359. | homo-2-mer | 2×S8B; 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease with covalent inhibitor | homo-2-mer | 1×BTB; 2×A1AD0; 13×DMS; 2×EDO; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main protease mutant M49I in complex with Ensitrelvir | homo-2-mer | 3×DMS; 2×7YY; | ||||
| Assess | ||||||
| Room temperature X-ray crystallography reveals catalytic cysteine in the SARS-CoV-2 3CL Mpro is hig… | homo-2-mer | 4×NEN; 2×DMS; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI20 | homo-2-mer | 2×7XK; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Mpro with compound C3 | homo-2-mer | 2×P6R; | ||||
| Assess | ||||||
| The crystal structure of 3CL MainPro of SARS-CoV-2 with C145S mutation | homo-2-mer | 1×EDO; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-71 | homo-2-mer | 2×5ZT; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI6 | homo-2-mer | 2×VHP; | ||||
| Assess | ||||||
| Room temperature X-ray structure of SARS-CoV-2 main protease (Mpro) in complex with HL-3-63 | homo-2-mer | 2×5ZJ; | ||||
| Assess | ||||||
| Structure of SARS-CoV2 NSP5 (3C-like proteinase) determined in-house | homo-2-mer | |||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) variant C44S at 2.12 A resolution | homo-2-mer | 1×DMS; | ||||
| Assess | ||||||
| Structure of SARS-CoV2 3CL protease covalently bound to peptidomimetic inhibitor | homo-2-mer | 2×YWJ; | ||||
| Assess | ||||||
| Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors | homo-2-mer | 2×4IT; | ||||
| Assess | ||||||
| Co-crystal structure of SARS-CoV-2 Mpro with Pomotrelvir | homo-2-mer | 2×ZQB; | ||||
| Assess | ||||||
| Discovery of SARS-CoV-2 3CLpro peptidomimetic inhibitors through H41-specific protein-ligand intera… | homo-2-mer | 2×3XI; | ||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease in complex with an inhibitor N3 | homo-2-mer | |||||
| Assess | ||||||
| SARS-Cov2 Main protease in complex with inhibitor CDD-1845 | homo-2-mer | 2×O5F; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) Double Mutant (T21I and E166V) in Complex with… | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Mpro of SARS COV-2 in complex with the MG-87 inhibitor | homo-2-mer | 2×MXU; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS CoV2 main protease in complex with EG009 (modelled using PanDDA event map) | homo-2-mer | 4×DMS; 1×USH; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) at 277 K | homo-2-mer | 4×DMS; 2×ZN; | ||||
| Assess | ||||||
| Ensemble refinement structure of SARS-CoV-2 main protease (Mpro) at 277 K | homo-2-mer | 4×DMS; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CL pro) in complex with a novel inhibitor | homo-2-mer | 2×3WL; | ||||
| Assess | ||||||
| Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Boceprevir | homo-2-mer | 2×U5G; | ||||
| Assess | ||||||
| Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Leupeptin | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) F140L Mutant in Complex with Inhibitor Nirmatr… | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI37 | homo-2-mer | 2×WOH; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI29 | homo-2-mer | 2×8G9; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main protease in complex with Ensitrelvir | homo-2-mer | 3×DMS; 2×7YY; | ||||
| Assess | ||||||
| Room-temperature X-ray Crystal structure of SARS-CoV-2 main protease in complex with Narlaprevir | homo-2-mer | 2×NNA; | ||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| Structural Plasticity of the SARS-CoV-2 3CL Mpro Active Site Cavity Revealed by Room Temperature X-… | homo-2-mer | |||||
| Assess | ||||||
| SARS Coronavirus-2 Main Protease 3CL-pro binding Ascorbate | homo-2-mer | 2×ASC; 2×ETF; | ||||
| Assess | ||||||
| Complex Structure of SARS-CoV-2 3CL Protease with TG-0203770 | homo-2-mer | 2×TG3; | ||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp7-nsp8 (C7) cut site sequence | homo-2-mer | 2×PO4; 8×PEG; | ||||
| Assess | ||||||
| SARS-CoV2 NSP5 in complex with a peptidomimetic ligand | homo-2-mer | 2×VQR; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) in Complex with Covalent Inhibitor Leup… | homo-2-mer | 8×DMS; | ||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp8-nsp9 (C8) cut site sequence | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Mpro at 2.4 A Resolution | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) K90R Mutant in Complex with Inhibitor nirmatre… | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI18 | homo-2-mer | 2×7W5; | ||||
| Assess | ||||||
| SARS CoV2 Mpro C145S mutant | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in its apo-form | homo-2-mer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI16 | homo-2-mer | 2×7VW; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) variant K61A at 2.48 A resolution | homo-2-mer | 4×DMS; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in its apo-form | homo-2-mer | |||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI21 | homo-2-mer | 2×7XT; | ||||
| Assess | ||||||
| SARS CoV-2 MAIN PROTEASE 3CLpro, ROOM TEMPERATURE, DAMAGE FREE XFEL MONOCLINIC STRUCTURE | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in its apo-form | homo-2-mer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI36 | homo-2-mer | 2×8I0; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI28 | homo-2-mer | 2×800; | ||||
| Assess | ||||||
| SARS CoV-2 Mpro in complex with D-3-149 | homo-2-mer | |||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI34 | homo-2-mer | 2×8H3; | ||||
| Assess | ||||||
| Mpro of SARS COV-2 in complex with the MG-100 inhibitor | homo-2-mer | 2×MFL; 1×CL; | ||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp9-nsp10 (C9) cut site sequence | homo-2-mer | 2×NA; 3×1PE; 9×PEG; 5×PO4; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Omicron Main Protease (Mpro) in Complex with Nirmatrelvir | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Polymorphism in SARS-CoV-2 Nsp5 main protease reveals differences in cleavage of viral and host sub… | homo-2-mer | |||||
| Assess | ||||||
| Joint X-ray/neutron structure of SARS-CoV-2 main protease (3CL Mpro) in complex with BBH-1 | homo-2-mer | 2×I1W; | ||||
| Assess | ||||||
| Joint X-ray/neutron structure of SARS-CoV-2 main protease (3CL Mpro) in complex with Telaprevir | homo-2-mer | 2×SV6; | ||||
| Assess | ||||||
| Joint neutron/X-ray structure of SARS-CoV-2 3CL Mpro at room temperature | homo-2-mer | |||||
| Assess | ||||||
| Joint X-ray/neutron structure of SARS-CoV-2 main protease (Mpro) in complex with Mcule5948770040 | homo-2-mer | 2×YD1; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease with unliganded active site (2019-nCoV, coronavirus disease 2019, COVID-19… | homo-2-mer | 14×DMS; 2×PEG; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease in a covalent complex with a pyridine derivative of ABT-957, compound 1 | homo-2-mer | 8×DMS; 2×R8H; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-CoV-2 MAIN PROTEASE COMPLEXED WITH GC376 | homo-2-mer | 2×K36; 1×DMS; | ||||
| Assess | ||||||
| Structure of apo SARS-CoV-2 Main Protease with large beta angle, space group C2. | homo-2-mer | 2×CL; 12×DMS; | ||||
| Assess | ||||||
| Structure of apo SARS-CoV-2 Main Protease with small beta angle, space group C2. | homo-2-mer | 10×DMS; | ||||
| Assess | ||||||
| Structure of SARS-Cov2 3CLPro in complex with Compound 34 | homo-2-mer | 2×X8F; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (no ligand) | homo-2-mer | 8×DMS; | ||||
| Assess | ||||||
| X-ray Structure of SARS-CoV-2 main protease bound to GRL-024-20 at 1.45 A | homo-2-mer | 2×V7G; | ||||
| Assess | ||||||
| SARS-CoV2 Mpro native form | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 13 | homo-2-mer | 8×DMS; 2×TU8; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 Main Protease with oxidized C145 | homo-2-mer | 10×DMS; 2×GOL; 18×FMT; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease Co-Crystal Structure with Telaprevir Determined from Crystals Grown with 4… | homo-2-mer | 2×DMS; 2×SV6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 14×DMS; 2×P7R; 2×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RDQ; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 Main Protease complexed with N-(pyridin-3-ylmethyl)thioformamide | homo-2-mer | 2×35J; 6×NA; 14×FMT; 10×DMS; | ||||
| Assess | ||||||
| Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of… | homo-2-mer | 2×JKL; | ||||
| Assess | ||||||
| Native 3CLpro from SARS-CoV-2 at 1.54 A | homo-2-mer | |||||
| Assess | ||||||
| The crystal structure of 3CL MainPro of SARS-CoV-2 with de-oxidized C145 | homo-2-mer | 4×EDO; 4×FMT; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 1 | homo-2-mer | 2×SQ5; 9×DMS; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 5 | homo-2-mer | 2×SQ2; 2×PEG; 10×DMS; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-12 | homo-2-mer | 1×VXQ; 8×DMS; 1×NA; 1×CL; | ||||
| Assess | ||||||
| Structure of SARS-Cov2 3CLPro in complex with Compound 33 | homo-2-mer | 2×X83; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 20×DMS; 2×OQL; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 19×DMS; 2×P3L; 2×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 1×CL; 2×RDK; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 2×QO0; 1×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to PD 168568. | homo-2-mer | 2×CL; 14×DMS; 2×RMZ; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 8 | homo-2-mer | 12×DMS; 2×T0W; | ||||
| Assess | ||||||
| Viral protease | homo-2-mer | 6×HYR; 4×DMS; 4×SO4; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (Mpro) Mutant (S144A) in complex with protease inhibi… | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 16×DMS; 2×PQ6; 1×CL; | ||||
| Assess | ||||||
| Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of… | homo-2-mer | 2×JK0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×RR0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 16×DMS; 2×P9O; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-29 | homo-2-mer | 6×DMS; 3×XXN; 1×SO4; 1×MG; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 2×PJ6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×RD5; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2 (2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 4 | homo-2-mer | 2×XEY; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to 2,4'-Dimethylpropiophenone. | homo-2-mer | 8×DMS; 2×R7Q; 2×IMD; 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease Co-Crystal Structure with Telaprevir Determined from Crystals Grown with 4… | homo-2-mer | 2×DMS; 2×SV6; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 21 | homo-2-mer | 6×DMS; 2×U7W; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 2×OZX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 2×P4R; 1×CL; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 15 | homo-2-mer | 2×U9H; 7×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×RZF; | ||||
| Assess | ||||||
| Crystal structure of the main protease (3CLpro/Mpro) of SARS-CoV-2 at 1.65A resolution (spacegroup … | homo-2-mer | |||||
| Assess | ||||||
| X-ray Structure of SARS-CoV-2 main protease covalently modified by compound GRL-091-20 | homo-2-mer | 2×4I9; 2×NA; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 6 | homo-2-mer | 12×DMS; 2×SYH; | ||||
| Assess | ||||||
| X-ray Structure of SARS-CoV-2 main protease covalently modified by compound GRL-017-20 | homo-2-mer | 2×4IJ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 1×CL; 2×QRF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 2×OZC; 2×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RVR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 14×DMS; 2×OVX; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of F2F-2020197-00X bound to the main protease (3CLpro/Mpro) of SARS-CoV-2. | homo-2-mer | 2×84C; 4×CL; 2×BR; 1×DMS; 1×MPD; 1×EDO; 1×NA; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound 3 | homo-2-mer | 2×P0O; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×R8X; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Fusidic Acid. | homo-2-mer | 2×FUA; 10×DMS; 4×IMD; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×RW0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 1×CL; 2×R95; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 2×CL; 2×R5O; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×REU; | ||||
| Assess | ||||||
| Crystal structure of MG-132 covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 in ab… | homo-2-mer | 10×EDO; 2×ALD; 1×CL; 1×NA; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to AT7519 | homo-2-mer | 2×LZE; 4×CL; 16×DMS; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Maleate. | homo-2-mer | 4×CL; 12×DMS; 2×SIN; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 2×QER; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 2×QFL; | ||||
| Assess | ||||||
| Crystal structure of MG-132 covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2. | homo-2-mer | 2×ALD; 13×EDO; 1×PEG; 1×NA; 1×CL; | ||||
| Assess | ||||||
| Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of… | homo-2-mer | 2×JJO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 1×CL; 2×RW9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×R7F; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 1×CL; 2×RWT; | ||||
| Assess | ||||||
| 1.7A resolution structure of SARS-CoV-2 main protease (Mpro) in complex with broad-spectrum coronav… | homo-2-mer | 1×NA; 2×K36; 2×B1S; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-23 | homo-2-mer | 5×DMS; 1×XZE; 2×NA; 1×CL; | ||||
| Assess | ||||||
| Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of… | homo-2-mer | 2×JKL; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CL pro) apo structure (space group C21) | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (Mpro) in complex with the HCV NS3/4A inhibitor telap… | homo-2-mer | 2×CL; 2×SV6; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM139 | homo-2-mer | 2×YVD; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144A Mutant | homo-2-mer | |||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×RGX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×R3I; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-16 | homo-2-mer | 1×Y0L; 9×DMS; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×R76; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×QCC; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×RT4; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 3×CL; 2×R66; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 2×QBR; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×RI6; | ||||
| Assess | ||||||
| Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of… | homo-2-mer | 2×JJC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×OE6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RS6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×RPK; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×ROZ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RWO; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-6 | homo-2-mer | 6×DMS; 2×Y1L; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 1×CL; 2×R9Z; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML1006m | homo-2-mer | 2×90H; 2×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 15×DMS; 1×CL; 2×S1L; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RGQ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×CL; 2×R4X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RFF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×QXI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 1×CL; 2×RXU; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) H172Y Mutant | homo-2-mer | 1×GOL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 1×CL; 1×R8I; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound 1 | homo-2-mer | 2×OZ6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RYB; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×O0X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 2×OWC; 3×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×QYR; | ||||
| Assess | ||||||
| The SARS-CoV2 major protease (Mpro) apo structure to 1.8 A resolution | homo-2-mer | 2×NA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 14 | homo-2-mer | 2×XF4; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Main Protease in complex with covalently bound GC376 | homo-2-mer | 6×DMS; 2×UED; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 1×CL; 2×QXR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 17×DMS; 2×QDF; 3×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RJF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RDX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×RRD; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×CL; 2×R43; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×R2L; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×QZL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to TH-302. | homo-2-mer | 2×S8E; 10×DMS; 2×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 2×QJL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×S39; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×RJO; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144A Mutant in Complex with Inhibitor GC376 | homo-2-mer | 2×K36; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM145 | homo-2-mer | 2×YVV; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×KG9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×R9R; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 Main Protease with a Zinc ion coordinated in the active site | homo-2-mer | 6×NA; 4×DMS; 10×FMT; 2×ZN; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×RIY; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 3 | homo-2-mer | 4×DMS; 2×RY5; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Omicron Main Protease (Mpro) | homo-2-mer | |||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×R2X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RIJ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×RQ6; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease complexed with N-(pyridin-3-ylmethyl)thioformamide | homo-2-mer | 4×DMS; 2×35J; 8×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RBX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RN0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 2×QIQ; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×RQF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×QZU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 1×CL; 2×R9I; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RKC; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-2 | homo-2-mer | 2×XWZ; 9×DMS; 1×CL; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RL8; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RI1; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RKR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RJ3; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RJX; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML124N | homo-2-mer | 2×99W; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×QWL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 1×CL; 2×R6L; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×RLR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 1×QHU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RMI; | ||||
| Assess | ||||||
| Crystal Structure of SARS CoV-2 Mpro with Pfizer Intravenous Inhibitor PF-00835231 | homo-2-mer | 2×GOL; 2×V2M; 2×DMS; | ||||
| Assess | ||||||
| SARS-CoV-2 Main protease in orthorhombic space group | homo-2-mer | 14×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×QC3; 2×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RT9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RC9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×R2X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 1×CL; 2×R08; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 1×CL; 1×R1I; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×R5H; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 2×QK3; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RHI; | ||||
| Assess | ||||||
| Crystal structure of MG-132 covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 in sp… | homo-2-mer | 2×ALD; 1×ACT; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×R0F; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 2×Q0I; | ||||
| Assess | ||||||
| Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of… | homo-2-mer | 2×JVX; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-26 | homo-2-mer | 5×DMS; 1×JAH; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RG3; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in complex with nirmatrelvir alkyne | homo-2-mer | 2×OW1; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×RNI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×RPZ; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Mpro with compound C4 | homo-2-mer | 2×P6I; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 2×QF5; 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound 9 (simnotrelvir, SIM0417, SSD8432) | homo-2-mer | 2×PQL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×RPZ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×RRU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×RAQ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×R9E; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×RBM; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 2×QDU; 1×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor dFFCit-yne | homo-2-mer | 2×YVY; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×R0Q; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RL0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×QIM; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×860; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×QNU; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 16×DMS; 1×CL; 2×QYI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 2×QEX; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×QP0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 13×DMS; 2×PJ6; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×L6D; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×QXX; | ||||
| Assess | ||||||
| Crystal structure of SU3327 (halicin) covalently bound to the main protease (3CLpro/Mpro) of SARS-C… | homo-2-mer | 8×U88; 3×NO3; 2×CL; 1×SO4; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 4×DMS; 2×QM3; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×QSF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×R2X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×RFR; | ||||
| Assess | ||||||
| Crystal structure of MG-132 covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 in sp… | homo-2-mer | 2×ALD; 8×EDO; 6×IPA; 4×CL; 2×NA; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease in complex with covalent inhibitor | homo-2-mer | 2×YFK; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×QVJ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×QR5; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×QFU; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×QM3; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 25 | homo-2-mer | 2×YU4; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×CL; 2×R76; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×QY6; | ||||
| Assess | ||||||
| Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors | homo-2-mer | 2×U0R; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor dFFR-yne | homo-2-mer | 3×SO4; 2×YVP; 1×DIO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 2×QJR; 1×CL; | ||||
| Assess | ||||||
| Crystal structure (monoclinic form) of the complex resulting from the reaction between SARS-CoV-2 (… | homo-2-mer | 2×DMS; 2×O6K; | ||||
| Assess | ||||||
| Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of… | homo-2-mer | 2×JWI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×R87; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×QS3; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×QVG; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound 2 | homo-2-mer | 2×I1Z; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with nirmatrelvir | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main protease A193T mutant in complex with Nirmatrelvir | homo-2-mer | 5×DMS; 2×4WI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 1×QPQ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 2×R1U; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 1×CL; 2×QC3; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 1×QQ6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×QW1; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 2×PUU; 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM137 | homo-2-mer | 2×YV7; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×QTL; | ||||
| Assess | ||||||
| Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors | homo-2-mer | 2×U1R; | ||||
| Assess | ||||||
| Synthesis, X-Ray Crystallographic and Biological Activities of Covalent, Non-Peptidic Inhibitors of… | homo-2-mer | 2×JWO; | ||||
| Assess | ||||||
| Structure of Mpro in complex with FGA146 | homo-2-mer | 2×QQL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×R8O; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×QX3; | ||||
| Assess | ||||||
| Structure of the apo form of Mpro from SARS-CoV-2 | homo-2-mer | |||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 1×QN9; | ||||
| Assess | ||||||
| Mpro of SARS COV-2 in complex with the MG-97 inhibitor | homo-2-mer | 2×M9X; 1×CL; | ||||
| Assess | ||||||
| Co-structure of SARS-CoV-2 (COVID-19 with covalent pyrazoline based inhibitors) | homo-2-mer | 2×I3R; 2×IMD; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease S144A (Mpro S144A) in Complex with Nirmatrelvir (PF-07321332) | homo-2-mer | 2×4WI; 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease in complex with covalent inhibitor | homo-2-mer | 2×OW1; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×QCO; 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease (Mpro) covalently modified with a penicillin derivative | homo-2-mer | 2×IFO; 2×EDO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×QX9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×QIZ; | ||||
| Assess | ||||||
| A SARS-CoV2 major protease non-covalent ligand structure determined to 2.0 A resolution | homo-2-mer | 2×7IL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 1×QQO; | ||||
| Assess | ||||||
| Crystal Structure of SARS CoV-2 Mpro mutant L141R with Pfizer Intravenous Inhibitor PF-00835231 | homo-2-mer | 2×DMS; 2×V2M; 9×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 2×QKR; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with MI-23 | homo-2-mer | 2×GQU; 2×TRS; | ||||
| Assess | ||||||
| X-ray crystal structure of the SARS-CoV-2 main protease in space group P21. | homo-2-mer | |||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×QSX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RK6; | ||||
| Assess | ||||||
| Room temperature In-situ SARS-CoV-2 MPRO with bound ABT-957 | homo-2-mer | 2×R8H; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×RSL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 2×CL; 2×QV0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 1×CL; 2×QZC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RG9; | ||||
| Assess | ||||||
| Crystal structure of SARS CoV-2 3CL protease in complex with GSK4365096A | homo-2-mer | 2×A1ADS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×QLO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×QHI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×QKI; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 2×QML; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×RQO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 2×CL; 1×QWU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×QI4; 3×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×QE3; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) H164N Mutant | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor Jun10-90-3-C1 | homo-2-mer | 2×QAO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 2×OI4; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 2×QI7; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 1×CL; 2×QYN; | ||||
| Assess | ||||||
| Structure of the SARS-COV-2 main protease with 337 inhibitor | homo-2-mer | 2×G7L; | ||||
| Assess | ||||||
| Room-temperature structure of SARS-CoV-2 Main protease at atmospheric pressure | homo-2-mer | 4×DMS; | ||||
| Assess | ||||||
| Crystal structure of ebselen covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2. | homo-2-mer | 5×9JT; 7×EDO; 2×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 2×QIT; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 2×QP6; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 2×QV9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×QNU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×NM0; | ||||
| Assess | ||||||
| Crystal structure of SARS CoV2 main protease in complex with DN_EG_002 (modelled using PanDDA event… | homo-2-mer | 7×DMS; 1×US8; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 2×QH6; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×QZ0; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM129 | homo-2-mer | 2×YVA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×P4R; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×RM3; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Mpro mutant (K90R) in complex with Nirmatrelvir (PF-07321332) | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 2×QP6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 11×DMS; 2×QL3; 1×CL; | ||||
| Assess | ||||||
| Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors | homo-2-mer | 2×TNI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×QGX; 2×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×RVR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 2×QLC; 1×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Rupintrivir (P21) | homo-2-mer | 2×AG7; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 18×DMS; 2×Q0I; 5×CL; 1×CA; | ||||
| Assess | ||||||
| Structure of COVID-19 main protease bound to potent broad-spectrum non-covalent inhibitor X77 | homo-2-mer | 2×X77; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in complex with Y180 | homo-2-mer | 2×2RI; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 1×QOU; | ||||
| Assess | ||||||
| SARS-CoV-2 3CLPro in complex with N-[4-[[2-(benzotriazol-1-yl)acetyl]-(3-thienylmethyl)amino]phenyl… | homo-2-mer | 2×Y6J; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Mpro with C5a | homo-2-mer | 2×WZK; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 1×QQU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 2×QGC; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 1×QKB; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main protease in complex with Nirmatrelvir | homo-2-mer | 2×4WI; 3×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 1×PJX; 1×CL; | ||||
| Assess | ||||||
| Sars-Cov2 Main Protease in complex with CDD-1733 | homo-2-mer | 2×O5O; | ||||
| Assess | ||||||
| Crystal structure of SARS CoV2 main protease in complex with FSP006 | homo-2-mer | 6×DMS; 1×CL; 1×URK; 1×PEG; | ||||
| Assess | ||||||
| Crystal structure of SAR-CoV-2 3CL protease complex with inhibitor SH-5 | homo-2-mer | 2×HUO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RVL; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 21 | homo-2-mer | 1×XF7; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 1×QOC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 1×QF9; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×QRS; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) T135I Mutant | homo-2-mer | |||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 12×DMS; 2×QIB; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×QU9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×QT3; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 50 | homo-2-mer | 2×YTS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×RLH; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 2×QJ6; | ||||
| Assess | ||||||
| SARS-CoV-2 3CLPro in complex with 2-(benzotriazol-1-yl)-N-[4-(1H-imidazol-4-yl)phenyl]-N-(3-thienyl… | homo-2-mer | 2×Y6G; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 1×QIZ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 7×DMS; 1×CL; 2×QUQ; | ||||
| Assess | ||||||
| Crystal Structure of SARS CoV-2 Mpro mutant L50F with Nirmatrelvir captured in two conformational s… | homo-2-mer | 2×DMS; 2×4WI; 12×NA; 8×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 2×RIU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×QTC; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 23 | homo-2-mer | 1×YSJ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 1×CL; 1×QVU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 5×DMS; 1×QQF; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in complex with Boceprevir (space group P212121) | homo-2-mer | 2×U5G; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with AG7404 | homo-2-mer | 2×XNV; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) H172Q Mutant | homo-2-mer | |||||
| Assess | ||||||
| Structure of the SARS-COV-2 main protease with EN102 inhibitor | homo-2-mer | 2×G7O; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor Jun9-62-2R | homo-2-mer | 4×GOL; 2×SO4; 2×5ZF; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) H163A Mutant in Complex with GC376 | homo-2-mer | 2×DMS; 2×K36; | ||||
| Assess | ||||||
| Crystal structure of SARS CoV2 main protease in complex with FSCU015 | homo-2-mer | 4×DMS; 1×UQZ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 1×CL; 1×RV0; | ||||
| Assess | ||||||
| Room-temperature structure of SARS-CoV-2 Main protease at 104 MPa helium gas pressure in a sapphire… | homo-2-mer | 4×DMS; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main protease mutant Q189K in complex with Nirmatrelvir | homo-2-mer | 2×4WI; 3×DMS; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) M165Y Mutant in Complex with Nirmatrelvir | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML188 | homo-2-mer | 2×0EN; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×RTS; | ||||
| Assess | ||||||
| Structure of SARS-Cov2 3CLPro in complex with Compound 5 | homo-2-mer | 2×I70; 2×PO4; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Rupintrivir (P21212) | homo-2-mer | 2×AG7; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 1×QJF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 9×DMS; 1×CL; 1×QR9; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main protease A193S mutant in complex with Nirmatrelvir | homo-2-mer | 2×4WI; 2×DMS; | ||||
| Assess | ||||||
| SARS-CoV-2 Mpro (Omicron, P132H) in complex with alpha-ketoamide 13b-K at pH 6.5 | homo-2-mer | 2×O6K; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Calpeptin. | homo-2-mer | 2×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to Triglycidyl isocyanurate. | homo-2-mer | 2×S7H; 2×RV8; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) E166Q Mutant | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor dFFR | homo-2-mer | 2×H37; 1×SO4; | ||||
| Assess | ||||||
| Crystal Structure of SARS CoV-2 Mpro mutant N142P with Pfizer Intravenous Inhibitor PF-00835231 | homo-2-mer | 2×V2M; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) E166R Mutant in Complex with Inhibitor GC376 | homo-2-mer | 2×K36; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) E166N Mutant | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS CoV2 main protease in complex with FSP007 | homo-2-mer | 6×DMS; 1×UQW; | ||||
| Assess | ||||||
| Cryo-EM structure of SARS CoV-2 Mpro WT protease | homo-2-mer | |||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 4×DMS; 2×NJE; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×KU6; 6×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NKU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NEL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×L1F; 6×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×KOI; 8×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of ground-state model of SARS-CoV-2 main protease screened against… | homo-2-mer | 6×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 4×DMS; 2×N5L; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KMF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NIJ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 4×DMS; 2×KVX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×KJO; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×N6X; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z21… | homo-2-mer | 2×RZS; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×NQO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 4×DMS; 2×860; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LJ0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 6×DMS; 2×U0S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UHG; 10×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×NZK; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NYR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×MU3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of SARS-CoV-2 main protease ligands identified from single sequenc… | homo-2-mer | 6×DMS; 2×O4F; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O2R; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×KNU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O0X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OT6; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease with unliganded active site (2019-nCoV, coronavirus disease 2019, COVID-19) | homo-2-mer | 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LDX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NDI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KQX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LF3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×K1Y; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NVO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NOI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 4×DMS; 4×K1G; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q8O; 10×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×T6J; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LKX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×OOL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×KLR; 8×DMS; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM143 | homo-2-mer | 2×YVJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×S7D; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 6×DMS; 2×U0V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 10×DMS; 2×USD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T8M; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UGM; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O4L; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×SFY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 8×DMS; 2×NTG; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O3I; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor UAW246 | homo-2-mer | 3×GOL; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q69; 10×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OBO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×MZF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×PVR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×JGG; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OIE; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×KVF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NWI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NUR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×JJG; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NGX; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 Main Protease with the formation of Cys145-1H-indole-5-carboxyl… | homo-2-mer | 2×XC4; 2×EDO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q5C; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OUF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhi… | homo-2-mer | 2×VEM; 8×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T8J; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×K3S; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OGO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NB6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×P7R; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×OSI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NQ3; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KZC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NRX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×ODX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×T5V; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OGF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×KMX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×KXF; 6×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×M7X; | ||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease in complex with an inhibitor 11b | homo-2-mer | 8×DMS; 2×FJC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OQF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LZX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×N00; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×T8M; 8×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhi… | homo-2-mer | 8×DMS; 2×VEP; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OQX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×N9I; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OGV; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LWO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×M2X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q8I; 10×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UH1; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×PZ6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q3U; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×MQ3; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×Q7R; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NRC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×L4U; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×HVB; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of SARS-CoV-2 main protease ligands identified from single sequenc… | homo-2-mer | 6×DMS; 2×O3R; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhi… | homo-2-mer | 8×DMS; 2×VEV; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T8D; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×SQ2; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM141 | homo-2-mer | 2×YVG; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KZX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×T67; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LJO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LT9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NW0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×KW9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×KQ3; 8×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T4M; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 14×DMS; 2×OLX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OKW; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T8P; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OI4; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×M0G; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×L6R; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×L2I; 6×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q6U; 10×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LM0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q4R; 8×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UPD; 10×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×L7V; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O1X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OK9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q45; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×L8F; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 6×DMS; 2×U0P; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 14×DMS; 2×US7; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q2U; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 4×DMS; 2×LQU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OPU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O0C; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×L4N; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T8A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T6Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhi… | homo-2-mer | 8×DMS; 2×VEY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 10×DMS; 2×T9P; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×USA; 12×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of SARS-CoV-2 main protease ligands identified from single sequenc… | homo-2-mer | 10×DMS; 2×O46; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LV9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×K0G; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×ORR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×KVO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×L7F; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OD7; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 8×DMS; 2×HWH; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LO0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OQL; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor UAW247 | homo-2-mer | 2×GOL; 2×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OCI; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 Main Protease in complex with masitinib | homo-2-mer | 2×G65; 2×DMS; 4×GOL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×UHY; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OJ9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T4J; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×L5I; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LBC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NSR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LBO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×T5Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×6SU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×N2X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LS0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LW6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×KY0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×Q0I; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LQ0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×N8X; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T2G; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LXF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O1I; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×JGP; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×T9M; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×OV4; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×N0F; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OIX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T7G; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KU6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OFX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×N7L; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×M4L; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T3V; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OWX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×Q7C; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×M26; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T5D; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z45… | homo-2-mer | 2×JFM; 8×DMS; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with UAW241 | homo-2-mer | 2×GOL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×O9O; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×L93; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhi… | homo-2-mer | 2×VEJ; 8×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 6×DMS; 2×T9J; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×KSX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q2G; 6×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q60; 10×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×MX9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×N0X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×N4L; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×LWA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×L3I; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q36; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LRN; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×OWC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OIK; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T47; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 main protease in complex with GC376 | homo-2-mer | 2×K36; 2×B1S; 2×EDO; 4×CL; 2×K; 2×NA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 10×DMS; 2×T8V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×T0Y; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×P3L; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of computational designs of SARS-CoV-2 main protease covalent inhi… | homo-2-mer | 2×VEG; 10×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T71; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NM0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×L8O; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UHA; 6×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T4D; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UGP; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×PWR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LRC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×KS0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×U0M; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KYC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T84; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with UAW243 | homo-2-mer | 2×GOL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OEO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×N3R; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×M9U; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 4×DMS; 2×MF0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×KJI; 8×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×UJ1; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T81; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NU0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 10×DMS; 2×LPZ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 6×DMS; 2×S7V; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q4F; 10×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T1V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T8Y; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Main Protease after incubation with Sulfo-Calpeptin | homo-2-mer | 2×RN2; 3×DMS; 2×NA; 2×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 4×DMS; 2×M93; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UHV; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×KYU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OO6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×MWN; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NJU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with N… | homo-2-mer | 8×DMS; 2×T5G; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OYX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 8×DMS; 2×T1J; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OJO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×L7Q; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×MJR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×L83; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×KSI; 8×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T1Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 6×DMS; 2×U1G; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×HV2; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OVX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NO0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O9X; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×R30; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T7D; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LVM; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×Y6J; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×KL6; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×MVR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T7Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×U0Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×UPJ; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OHC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×M50; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KUU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×T1M; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×L9O; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OE6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LB0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×KT9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T6M; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T54; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 8×DMS; 2×T0S; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NB0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 8×DMS; 2×AWP; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×M5I; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T7P; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T7A; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OAO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KX9; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-7 | homo-2-mer | 5×DMS; 1×Y1H; 1×CL; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OYF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×L9F; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×M0X; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T3G; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×T0V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×UHM; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×LCU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×OQL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×M6I; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×P9O; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×T1S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UGG; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×MVX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UH7; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LR0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z31… | homo-2-mer | 2×GWS; 6×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T7S; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×N6F; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×OVF; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OZX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×N3I; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×N1U; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KP0; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×PQ6; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O8L; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LSF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×U1A; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-27 | homo-2-mer | 4×DMS; 1×XZ6; 1×CL; 1×SO4; 1×NA; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×MKI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KO9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×P6O; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×O0S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T2Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×SZY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T3J; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-28 | homo-2-mer | 3×0TI; 9×DMS; 2×SO4; 1×MG; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O0R; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×LKI; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with Covalent Inhibitor SM144 | homo-2-mer | 2×YVM; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) H172Y Mutant in Complex with Inhibitor GC376 | homo-2-mer | 2×K36; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×M5X; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T8S; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor UAWJ9-36-1 | homo-2-mer | 2×YHJ; 4×GOL; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor UAWJ9-36-3 | homo-2-mer | 2×GOL; 2×NA; 2×YHI; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×Q1C; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×P4R; | ||||
| Assess | ||||||
| Crystal structure of Zinc bound SARS-CoV-2 main protease | homo-2-mer | 3×ZN; 3×DMS; 2×GLY; 1×CL; 1×BTB; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×N0O; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×UJ4; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×L6D; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UH4; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NV9; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×PKW; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-18 | homo-2-mer | 2×Y0C; 7×DMS; 2×NA; 1×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×P0X; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×RZG; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×N43; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OTV; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O3U; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×KXR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of COVID-19 main protease in complex with Z13… | homo-2-mer | 2×RZJ; 8×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KQL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×M6U; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T4Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UGV; 8×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T2J; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×LUC; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O5C; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q5K; 8×DMS; 2×CL; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 10×DMS; 2×PJX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×Z26; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UGS; 10×DMS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×NX9; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 18 | homo-2-mer | 4×DMS; 2×V1B; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in complex with 32j | homo-2-mer | 2×OF9; 4×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) H164N Mutant in Complex with Inhibitor GC376 | homo-2-mer | 2×K36; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T7V; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144L Mutant in Complex with Inhibitor GC376 | homo-2-mer | 2×B1S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 6×DMS; 2×U1D; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease treated with ebselen | homo-2-mer | 2×SE; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×NSR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T7J; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×U1M; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 6×DMS; 2×T0J; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 8×DMS; 2×T4V; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease (Mpro) in complex with inhibitor Jun89… | homo-2-mer | 2×5ZF; | ||||
| Assess | ||||||
| Crystal structure of SARS CoV2 main protease in complex with inhibitor Boceprevir | homo-2-mer | 4×DMS; 2×U5G; | ||||
| Assess | ||||||
| Crystal structure of SARS CoV2 main protease in complex with inhibitor Telaprevir | homo-2-mer | 2×DMS; 2×SV6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 2×UGD; 8×DMS; | ||||
| Assess | ||||||
| Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors | homo-2-mer | 2×U2B; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T2V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 4×DMS; 2×U1V; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×KWR; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 2×Q5R; 10×DMS; | ||||
| Assess | ||||||
| Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors | homo-2-mer | 2×TKX; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×PUU; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×OZC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 8×DMS; 2×UHS; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×O87; | ||||
| Assess | ||||||
| PanDDA analysis group deposition SARS-CoV-2 main protease fragment screen -- Crystal Structure of S… | homo-2-mer | 6×DMS; 2×NZD; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 2×Q1U; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 8×DMS; 2×PJ6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with P… | homo-2-mer | 6×DMS; 2×T6V; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease in complex with a cyclic peptide inhibitor | homo-2-mer | |||||
| Assess | ||||||
| Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors | homo-2-mer | 1×U26; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) Covalently Bound to Compound C63 | homo-2-mer | 2×ZJ1; | ||||
| Assess | ||||||
| Virtual screening for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors | homo-2-mer | 2×U2I; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (3CLpro/Mpro) Covalently Bound to Compound C7 | homo-2-mer | 2×C7A; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) H164I Mutant | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) Q192T Mutant in Complex with Inhibitor GC376 | homo-2-mer | 2×B1S; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease in complex with PF07321332 in spacegroup P1211 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease in complex with an inhibitor 11a | homo-2-mer | 8×DMS; 2×FHR; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL in complex with inhibitor NK01-63 | homo-2-mer | 2×N63; 2×NA; 2×EDO; 2×SCN; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 main protease in complex with 14b | homo-2-mer | 2×0AX; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Mpro Omicron P132H in complex with Nirmatrelvir (PF-07321332) | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| The co-crystal structure of SARS-CoV-2 main protease with peptidomimetic inhibitor (S)-2-cinnamamid… | homo-2-mer | 2×H60; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL in complex with inhibitor NK01-14 | homo-2-mer | 2×XTP; 2×SCN; | ||||
| Assess | ||||||
| Crystal structure of SAR-CoV-2 3CL protease complex with inhibitor YH-53 | homo-2-mer | 2×HUR; 14×EDO; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease V186F mutant in complex with CCF0058981 | homo-2-mer | 2×XIU; | ||||
| Assess | ||||||
| The co-crystal structure of SARS-CoV-2 main protease with (S)-2-cinnamamido-4-methyl-N-((S)-1-oxo-3… | homo-2-mer | 2×EOF; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL in complex with inhibitor EB54 | homo-2-mer | 2×I54; 2×PO4; | ||||
| Assess | ||||||
| Structure of the hemiacetal complex between the SARS-CoV-2 Main Protease and Leupeptin | homo-2-mer | 8×DMS; 2×IMD; 2×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 3CLpro | homo-2-mer | 2×5IZ; | ||||
| Assess | ||||||
| SARS-CoV-2 3CLpro | homo-2-mer | 2×5IW; | ||||
| Assess | ||||||
| Crystal Structure of uncleaved SARS-CoV-2 Main Protease C145S mutant in complex with Nirmatrelvir | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Room-temperature X-ray structure of SARS-CoV-2 main protease double mutant E290A/R298A in complex w… | homo-2-mer | 2×UED; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 11 | homo-2-mer | 1×YSG; | ||||
| Assess | ||||||
| Room-temperature X-ray structure of SARS-CoV-2 main protease H41A miniprecursor mutant in complex w… | homo-2-mer | 2×K36; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with GC376 | homo-2-mer | 2×UED; 4×PO4; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor 11 | homo-2-mer | 2×GOL; 2×U6Y; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 16 | homo-2-mer | 2×YSP; | ||||
| Assess | ||||||
| The co-crystal structure of SARS-CoV-2 main protease with the peptidomimetic inhibitor (S)-2-cinnam… | homo-2-mer | 2×H6R; | ||||
| Assess | ||||||
| SARS-CoV-2 3CLpro | homo-2-mer | 2×59S; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor 17 | homo-2-mer | 2×U76; 2×GOL; | ||||
| Assess | ||||||
| Crystal structure (orthorhombic form) of the complex resulting from the reaction between SARS-CoV-2… | homo-2-mer | 2×O6K; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with Robinetin | homo-2-mer | 2×LKR; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 19 | homo-2-mer | 1×YSM; | ||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp12-nsp13 (C12) cut site sequen… | homo-2-mer | 1×PEG; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with noncovalent inhibitor … | homo-2-mer | 2×X7V; 4×GOL; | ||||
| Assess | ||||||
| Covalent complex of SARS-CoV-2 main protease with N-[(2S)-1-({(2S,3S)-3,4-dihydroxy-1-[(3S)-2-oxopy… | homo-2-mer | 2×V2M; 1×EDO; | ||||
| Assess | ||||||
| Group deposition SARS-CoV-2 main protease in complex with inhibitors from the COVID Moonshot -- Cry… | homo-2-mer | 6×DMS; 4×ONU; | ||||
| Assess | ||||||
| Structure of SARS-Cov2 3CLPro in complex with Compound 27 | homo-2-mer | 2×XKQ; 20×EDO; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with an inhibitor TKB-245 | homo-2-mer | 2×T2L; 2×DMS; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) E166V Mutant in Complex with Inhibitor Enstrel… | homo-2-mer | 2×7YY; 4×GOL; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease with alternative conformation of the active site promoted by methylene-brid… | homo-2-mer | 6×DMS; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 14c | homo-2-mer | 2×FWI; 2×FZI; 1×PG4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 1c | homo-2-mer | 2×YMG; 2×YMD; 1×PG4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 17d | homo-2-mer | 2×PJR; 2×P8C; 1×PG4; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main protease G143S mutant in complex with Nirmatrelvir | homo-2-mer | 2×4WI; 1×DMS; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Mpro Lambda (G15S) in complex with Nirmatrelvir (PF-07321332) | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 main protease in complex with 14c | homo-2-mer | 2×0BO; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 main protease in complex with 14a | homo-2-mer | 2×06Q; | ||||
| Assess | ||||||
| 1.70 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 7j | homo-2-mer | 2×QYS; 1×PG4; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-9 | homo-2-mer | 12×DMS; 2×NA; 1×ZHA; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with MAC5576 | homo-2-mer | 2×LW1; 2×PO4; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 6 | homo-2-mer | 2×YTJ; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL in complex with inhibitor NK01-48 | homo-2-mer | 2×Y48; 4×PO4; 2×EDO; | ||||
| Assess | ||||||
| Room temperature X-ray structure of truncated SARS-CoV-2 main protease C145A mutant, residues 1-304… | homo-2-mer | 2×ZGI; | ||||
| Assess | ||||||
| Room temperature X-ray structure of truncated SARS-CoV-2 main protease C145A mutant, residues 1-304… | homo-2-mer | 2×ZGW; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) Double Mutant (L50F and E166V) in Complex with… | homo-2-mer | 2×7YY; 1×VIB; 1×GOL; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144F Mutant | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a m-chlorophenyl dimethyl sulfane inhi… | homo-2-mer | 1×CL; 2×VLU; 2×VM0; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-22 | homo-2-mer | 6×DMS; 1×NA; 1×XZI; 1×PO4; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease E166V (Apo structure) | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) H163A Mutant Apo Structure | homo-2-mer | 2×PGE; 1×NA; 2×PEG; 1×EDO; | ||||
| Assess | ||||||
| SARS-CoV-2 3CLPro in complex with 2-(benzotriazol-1-yl)-N-[4-(1H-pyrazol-4-yl)phenyl]-N-(3-thienylm… | homo-2-mer | 2×Y6A; | ||||
| Assess | ||||||
| Room temperature X-ray structure of truncated SARS-CoV-2 main protease C145A mutant, residues 1-304 | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with inhibitor TKB-248 | homo-2-mer | 2×T43; 2×DMS; 2×ZN; | ||||
| Assess | ||||||
| Room temperature X-ray structure of truncated SARS-CoV-2 main protease C145A mutant, residues 1-304… | homo-2-mer | 2×ZH0; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Main Protease bound to thioglucose. | homo-2-mer | 2×RVW; 4×DMS; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL in complex with inhibitor EB56 | homo-2-mer | 2×Q56; 2×MG; | ||||
| Assess | ||||||
| Room temperature X-ray structure of truncated SARS-CoV-2 main protease C145A mutant, residues 1-304… | homo-2-mer | 2×ZGO; | ||||
| Assess | ||||||
| Sars-Cov2 Main Protease in complex with CDD-1819 | homo-2-mer | 2×O69; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) N28T Mutant | homo-2-mer | |||||
| Assess | ||||||
| Crystals Structure of the SARS-CoV-2 (COVID-19) main protease with inhibitor GC-376 | homo-2-mer | 2×K36; 2×PEG; 2×GOL; 6×CL; 2×MG; | ||||
| Assess | ||||||
| SARS-CoV-2 3CLPro in complex with N-(4-(1H-pyrazol-4-yl)phenyl)-N-(3-chlorobenzyl)-2-(pyridin-3-yl)… | homo-2-mer | 2×I2D; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor Jun9-57-3R | homo-2-mer | 4×GOL; 2×5ZB; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) Double Mutant (T21I and E166V) in Complex with… | homo-2-mer | 2×7YY; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound 3w | homo-2-mer | 2×9FF; | ||||
| Assess | ||||||
| SARS-CoV-2 3CLPro in complex with N-(4-(1H-imidazol-4-yl)phenyl)-N-(3-chloro-5-fluorobenzyl)-2-(iso… | homo-2-mer | 2×I2N; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (Mpro) in complex with the HCV NS3/4A inhibitor bocep… | homo-2-mer | 2×U5G; 2×CL; | ||||
| Assess | ||||||
| Mpro of SARS COV-2 in complex with the RK-90 inhibitor | homo-2-mer | 2×MJ0; 1×CL; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor Jun10221 | homo-2-mer | 2×Y0E; 1×Y1E; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in complex with 11a | homo-2-mer | 2×UWO; | ||||
| Assess | ||||||
| SARS-CoV-2 Mpro 1-302 c145a in complex with peptide 4 | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 Mpro 1-302/C145A in complex with peptide 8-1 | homo-2-mer | |||||
| Assess | ||||||
| SARS CoV-2 Mpro 1-302 C145A in complex with peptide 7 | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease in complex with an inhibitor GRL-2420 | homo-2-mer | 2×V7G; 1×1PE; | ||||
| Assess | ||||||
| Crystal structure of SARS Cov-2 main protease in complex with an inhibitor 57 | homo-2-mer | 2×DMS; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with PF07321332 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound 3af | homo-2-mer | 2×QNC; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a dimethyl phenyl sulfane inhibitor (c… | homo-2-mer | 2×XCK; 1×PG4; | ||||
| Assess | ||||||
| The Crystal structure of deuterated S-217622 (Ensitrelvir) bound to the main protease (3CLpro/Mpro)… | homo-2-mer | 2×7YY; 1×GOL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 main protease in complex with Z… | homo-2-mer | 4×DMS; 2×JGY; | ||||
| Assess | ||||||
| 1.55 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 3c | homo-2-mer | 2×Y4J; 2×Y64; 1×EDO; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Omicron Main Protease (Mpro) in Complex with Ensitrelvir | homo-2-mer | 2×7YY; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 Main Protease in complex with demethylated analog of masitinib | homo-2-mer | 2×XNJ; 8×DMS; 8×GOL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with an inhibitor TKB-198 | homo-2-mer | 1×1PE; 1×MES; 2×DMS; 1×PG0; 2×T1X; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) K90R Mutant in Complex with Inhibitor ensitrel… | homo-2-mer | 2×7YY; | ||||
| Assess | ||||||
| SARS-CoV-2 Main protease immature form - apo structure | homo-2-mer | 7×DMS; 5×PEG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 2c | homo-2-mer | 2×FIK; 2×FIW; 2×PG4; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease complexed with Boceprevir | homo-2-mer | 2×U5G; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a dimethyl phenyl sulfane inhibitor | homo-2-mer | 2×XFF; 2×XFR; 1×PG4; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL in complex with inhibitor EB46 | homo-2-mer | 2×V46; 2×PO4; 2×MG; | ||||
| Assess | ||||||
| 1.65 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 3b (deuterated ana… | homo-2-mer | 1×Y4D; 1×Y5S; 1×Y8Y; 1×Y91; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) G15S Mutant in Complex with Inhibitor ensitrel… | homo-2-mer | 2×7YY; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-14 | homo-2-mer | 4×DMS; 1×Y0O; 2×SO4; 1×MG; | ||||
| Assess | ||||||
| Co-Crystal structure of the SARS-CoV2 main protease Nsp5 with an Uracil-carrying X77-like inhibitor | homo-2-mer | 1×MLI; 4×YQN; 2×NA; 1×DMS; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 15d | homo-2-mer | 2×P8U; 2×P8L; 1×PG4; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a dimethyl sulfinyl benzene inhibitor | homo-2-mer | 2×UO9; 2×URR; 1×PG4; | ||||
| Assess | ||||||
| THE CRYSTAL STRUCTURE OF COVID-19 MAIN PROTEASE IN COMPLEX WITH AN INHIBITOR N3 at 1.7 angstrom | homo-2-mer | |||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease treated by GA | homo-2-mer | 4×AU; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in complex with INZ-1 | homo-2-mer | 2×GKF; 2×GOL; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a phenyl sulfane inhibitor | homo-2-mer | 2×UV2; 2×UUR; 1×PG4; | ||||
| Assess | ||||||
| X-ray crystal structure of the SARS-CoV-2 main protease with Calpain I Inhibitor | homo-2-mer | 2×SO4; | ||||
| Assess | ||||||
| The native crystal structure of COVID-19 main protease | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of myricetin covalently bound to the main protease (3CLpro/Mpro) of SARS-CoV-2 | homo-2-mer | 10×EDO; 1×CL; 2×MYC; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease with narlaprevir | homo-2-mer | 2×NNA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE SARS-COV-2(2019-NCOV) MAIN PROTEASE IN COMPLEX WITH COMPOUND 29 | homo-2-mer | 2×YTV; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-5 | homo-2-mer | 5×DMS; 2×Y1R; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of the 2019-nCoV main protease complexed with Boceprevir | homo-2-mer | 2×U5G; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a dimethyl sulfonyl benzene inhibitor | homo-2-mer | 2×WJB; 2×UQO; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL in apo form | homo-2-mer | 2×PO4; | ||||
| Assess | ||||||
| The Crystal Structure of SARS-CoV-2 Omicron Mpro (P132H) in complex with demethylated analog of mas… | homo-2-mer | 2×XNJ; 4×DMS; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144L Mutant | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) in Complex with ML101 | homo-2-mer | 2×90U; 2×PGE; 2×PEG; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 3C-like protease Double Mutant (L50F and E166V) in complex with… | homo-2-mer | 2×ODN; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-19 | homo-2-mer | 10×DMS; 2×XZX; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with cpd-10 | homo-2-mer | 10×DMS; 1×Y0W; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (2019-NCoV) main protease in complex with 5-(3-{3-chloro-5-[(5-… | homo-2-mer | 2×06I; | ||||
| Assess | ||||||
| Crystal structure of SARS Cov-2 main protease in complex with an inhibitor 4 | homo-2-mer | 4×DMS; | ||||
| Assess | ||||||
| Crystal structure of apo SARS-CoV-2 main protease | homo-2-mer | |||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 3CL protease in complex with compound 1 | homo-2-mer | 2×7XB; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 complexed with GC376 | homo-2-mer | 2×K36; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with RAY1216 | homo-2-mer | 2×7ON; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with Z-IETD-FMK | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL in complex with inhibitor EB48 | homo-2-mer | 2×W48; 2×MG; | ||||
| Assess | ||||||
| SARS-CoV-2 Main protease immature form - FMAX Library E01 fragment | homo-2-mer | 11×PEG; 1×X4P; 8×DMS; 1×SER; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease in complex with LON-WEI-adc59df6-47 | homo-2-mer | 1×USZ; 9×DMS; 1×CL; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 2.10 A resolution-6 | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 2.10 A resolution-2 | homo-2-mer | |||||
| Assess | ||||||
| Ambient-Temperature Serial Femtosecond X-ray Crystal structure of SARS-CoV-2 Main Protease at 2.1 A… | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with myricetin | homo-2-mer | 2×MYC; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 2.10 A resolution-3 | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with (R)-1a | homo-2-mer | 2×2XI; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 3C-like protease in complex with a traditional Chinese Medicine… | homo-2-mer | 2×ODN; | ||||
| Assess | ||||||
| SARS-CoV-2 Main protease immature form - FMAX Library E09 fragment | homo-2-mer | 6×DMS; 5×PEG; 1×X4V; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 2.10 A resolution-8 | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL in complex with inhibitor SL-4-241 | homo-2-mer | 2×S4L; 2×ACT; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with Tafenoquine | homo-2-mer | 2×H3F; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) S144M Mutant | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 Main protease immature form - F2X Entry Library G05 fragment | homo-2-mer | 6×DMS; 4×PEG; 1×XY4; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 2.20 A resolution-10 | homo-2-mer | |||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 2.20 A resolution-12 | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 Main protease immature form - F2X Entry Library E06 fragment | homo-2-mer | 3×PEG; 6×DMS; 2×R9V; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 main protease (Nsp5) in complex with compound 17 | homo-2-mer | 2×V18; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 2.25 A resolution-13 | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a m-fluorodimethyl oxybenzene inhibitor | homo-2-mer | 2×WIO; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 1c | homo-2-mer | 2×ISG; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the inhibitor GC-67 | homo-2-mer | 2×KKO; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with 7-O-methyl-dihydromyricetin | homo-2-mer | 2×HF0; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease adduct with Au(PEt3)Br | homo-2-mer | 4×AU; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Mpro at 2.4 A resolution-11 | homo-2-mer | |||||
| Assess | ||||||
| SARS-COV-2 Main Protease adduct with Au(NHC)Cl | homo-2-mer | 2×AU; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with a covalent inhibitor | homo-2-mer | 2×80X; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with inhibitor Jun10541R | homo-2-mer | 2×Y0I; | ||||
| Assess | ||||||
| SARS-CoV-2 3CLpro | homo-2-mer | 2×EDO; 2×KM6; | ||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease treated by AF | homo-2-mer | 4×AU; | ||||
| Assess | ||||||
| SARS-CoV-2 Main protease immature form - F2X Entry Library E03 fragment | homo-2-mer | 4×PEG; 6×DMS; 1×XWS; | ||||
| Assess | ||||||
| 1.50 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 2k | homo-2-mer | 2×Y7M; 2×Y4V; 1×FLC; 2×PG4; | ||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp10-nsp11 (C10) cut site sequen… | homo-2-mer | 1×NA; | ||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp6-nsp7 (C6) cut site sequence … | homo-2-mer | |||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 13d | homo-2-mer | 2×IT3; 2×ITG; 1×PG4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 8b | homo-2-mer | 2×SO4; 2×YMY; 2×YN1; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease crystallized under reducing conditions | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 main protease (Mpro) in a novel conformational state. | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a p-fluorodimethyl oxybenzene inhibitor | homo-2-mer | 2×WGO; 2×WGU; 1×PG4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Mpro in complex with the nsp13-nsp14 (C13) cut site sequence (form 2) | homo-2-mer | 11×GOL; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a phenyl dimethyl sulfane inhibitor (c… | homo-2-mer | 2×XF8; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) K90R Mutant | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 main proteinase complex with microbial metabolite leupeptin | homo-2-mer | |||||
| Assess | ||||||
| 1.65 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 3d (deuterated ana… | homo-2-mer | 2×Y8S; 2×Y8V; 1×CL; 1×PO4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 10c | homo-2-mer | 2×FV5; 2×FVE; | ||||
| Assess | ||||||
| Crystal Structure of SARS-CoV-2 Main Protease (Mpro) G15S Mutant | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 main protease in complex with Z-VAD-FMK | homo-2-mer | |||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp6-nsp7 (C6) cut site sequence | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound JZD-07 | homo-2-mer | 2×KAE; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 3CL protease in complex with Ensitrelvir | homo-2-mer | 2×7YY; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease treated with ebselen derivative of MR6-31-2 | homo-2-mer | 2×SE; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease mutant (P168A) in complex with MG-132 | homo-2-mer | 2×ALD; 2×MG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 9c | homo-2-mer | 2×CL; 2×FHS; 2×FEY; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease in complex with PF07321332 in spacegroup P212121 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp13-nsp14 (C13) cut site sequen… | homo-2-mer | 3×PEG; 5×TRS; 2×1PE; 1×NA; | ||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp4-nsp5 (C4) cut site sequence | homo-2-mer | 1×NA; | ||||
| Assess | ||||||
| Crystal structure of the 2019-nCoV main protease | homo-2-mer | |||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound 3a | homo-2-mer | 2×UZF; | ||||
| Assess | ||||||
| crystal structure of SARS-CoV-2 3CL protease | homo-2-mer | |||||
| Assess | ||||||
| The Crystal Structure of SARS-CoV-2 Omicron Mpro (P132H) in complex with masitinib | homo-2-mer | 2×G65; | ||||
| Assess | ||||||
| wild-type SARS-CoV-2 main protease in complex with MG-132 | homo-2-mer | 2×MG; 2×ALD; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Mpro in complex with nsp12-nsp13 (C12) cut site sequence | homo-2-mer | 1×NA; 1×PEG; | ||||
| Assess | ||||||
| Product structure of SARS-CoV-2 Mpro C145A mutant in complex with nsp14-nsp15 (C14) cut site sequen… | homo-2-mer | 1×PEG; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease in complex with Z-DEVD-FMK | homo-2-mer | |||||
| Assess | ||||||
| the complex structure of SARS-CoV-2 Mpro with D8 | homo-2-mer | 2×OU3; | ||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease in complex with GC376 | homo-2-mer | 2×K36; | ||||
| Assess | ||||||
| SARS-CoV-2 3CL protease (3CLpro) in complex with compound 7 | homo-2-mer | 2×OZL; | ||||
| Assess | ||||||
| X-ray crystal structure of the SARS-CoV-2 main protease in space group C2 | homo-2-mer | |||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 4c | homo-2-mer | 2×ESS; 2×ET6; 1×PG4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 8c | homo-2-mer | 2×F8C; 2×F5L; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with PF07321332 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with inhibitor YH-53 | homo-2-mer | 2×HUR; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease P132H mutant in complex with inhibitor YH-53 | homo-2-mer | 2×HUR; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with inhibitor YH-53 | homo-2-mer | 2×HUR; | ||||
| Assess | ||||||
| 1.60 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 3e | homo-2-mer | 2×Y51; 2×Y71; 1×PG4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 10d | homo-2-mer | 2×IRW; 2×ITX; 1×CL; 1×PG4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 14c | homo-2-mer | 2×YKV; 2×YKS; | ||||
| Assess | ||||||
| 1.65 A resolution structure of SARS-CoV-2 3CL protease in complex with a deuterated GC376 alpha-ket… | homo-2-mer | 2×VR4; 1×PG4; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease V186F mutant in complex with PF07321332 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease V186F mutant in complex with PF00835231 | homo-2-mer | 2×V2M; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 3c | homo-2-mer | 2×FN2; 2×FP8; 1×PG4; | ||||
| Assess | ||||||
| 1.70 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 2f | homo-2-mer | 2×Y7G; 2×Y4P; 1×PG4; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease V186F mutant in complex with PF07304814 | homo-2-mer | 2×80I; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease P132H mutant in complex with PF00835231 | homo-2-mer | 2×V2M; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease P132H mutant in complex with S217622 | homo-2-mer | 2×7YY; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease Y54C mutant in complex with inhibitor YH-53 | homo-2-mer | 2×HUR; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with S217622 | homo-2-mer | 2×7YY; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a benzimidazole dimethyl sulfane inhib… | homo-2-mer | 2×WEL; 1×WEQ; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 21c | homo-2-mer | 2×YLV; 2×YM1; 1×PG4; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease Y54C mutant in complex with PF07304814 | homo-2-mer | 2×80I; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 11c | homo-2-mer | 2×EQS; 2×EO6; 1×PO4; 1×PG4; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 3CL protease in complex with compound 3 | homo-2-mer | 2×7YY; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a p-chlorodimethyl oxybenzene inhibitor | homo-2-mer | 2×WF5; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 3c | homo-2-mer | 2×YMJ; 2×YMM; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with inhibitor YH-53 | homo-2-mer | 2×HUR; | ||||
| Assess | ||||||
| Room-temperature X-ray structure of SARS-CoV-2 main protease H41A miniprecursor mutant | homo-2-mer | |||||
| Assess | ||||||
| 1.90 A resolution structure of SARS-CoV-2 3CL protease in complex with deuterated GC376 | homo-2-mer | 2×K36; 1×PG4; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease in complex with inhibitor YH-53 | homo-2-mer | 2×HUR; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease S46F mutant in complex with PF07304814 | homo-2-mer | 2×80I; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with S217622 | homo-2-mer | 2×7YY; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease K90R mutant in complex with PF07304814 | homo-2-mer | 2×80I; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 18c | homo-2-mer | 2×YLD; 2×YLJ; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 5c | homo-2-mer | 2×YMS; 2×YMV; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease M49I mutant in complex with PF07304814 | homo-2-mer | 2×80I; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease in complex with PF00835231 | homo-2-mer | 2×V2M; | ||||
| Assess | ||||||
| Oxidized form of SARS-CoV-2 Main Protease determined by XFEL radiation | homo-2-mer | 3×DMS; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 3CLpro with Zinc | homo-2-mer | 4×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 Main Protease (Mpro) H163A Mutant Reduced with 20mM TCEP | homo-2-mer | 1×GOL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 main protease in complex with a covalent inhibitor | homo-2-mer | 2×4YG; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 12b | homo-2-mer | 2×YKM; 2×YKP; 1×PG4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 19b | homo-2-mer | 2×YLM; 2×YLS; 1×PG4; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with PF07321332 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| 1.65 A resolution structure of SARS-CoV-2 3CL protease in complex with inhibitor 2a | homo-2-mer | 1×Y4D; 1×Y5S; 1×Y8Y; 1×Y91; 1×PG4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 7c | homo-2-mer | 2×EW9; 1×PG4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 17c | homo-2-mer | 2×YL7; 2×YKY; 1×PG4; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease P132H mutant in complex with PF07321332 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 13c | homo-2-mer | 2×YKA; 2×YKD; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CL protease in complex with a p-chlorophenylethanol based inhibitor | homo-2-mer | 1×CL; 2×WIX; 2×WJ0; | ||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease G15S mutant in complex with PF07304814 | homo-2-mer | 2×80I; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 main protease in complex with GC376 | homo-2-mer | 2×K36; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease (Mpro) apo structure (space group P212121) | homo-2-mer | |||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with inhibitor 20b (deuterated analog of 19b) | homo-2-mer | 2×YLM; 2×YLS; | ||||
| Assess | ||||||
| The crystal structure of COVID-2019 main protease in the apo state | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease S46F mutant in complex with PF07321332 | homo-2-mer | 2×4WI; | ||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease in the apo state | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-Cov-2 main protease in complex with PF07304814 | homo-2-mer | 1×80I; | ||||
| Assess | ||||||
| The crystal structure of COVID-19 main protease in complex with an inhibitor Shikonin | homo-2-mer | 1×FNO; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 6c | homo-2-mer | 2×IRZ; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 5c | homo-2-mer | 2×IS5; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 Macrodomain 3 (SARS-unique domain-M) | homo-2-mer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 Macrodomain 3 (SARS-unique domain-M) in complex with Oxaprozin | homo-2-mer | 2×BJ6; | ||||
| Assess | ||||||
| SARS-CoV-2 Nsp9 RNA-replicase | homo-2-mer | 3×SO4; | ||||
| Assess | ||||||
| Peptide-bound SARS-CoV-2 Nsp9 RNA-replicase | homo-2-mer | 2×PO4; | ||||
| Assess | ||||||
| The crystal structure of Nsp9 RNA binding protein of SARS CoV-2 | homo-2-mer | |||||
| Assess | ||||||
| Oridonin-bound SARS-CoV-2 Nsp9 | homo-2-mer | 2×ODN; 1×SO4; | ||||
| Assess | ||||||
| Peptide-bound SARS-CoV-2 Nsp9 RNA-replicase | homo-2-mer | 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of the ubiquitin-like domain 1 (Ubl1) of Nsp3 from SARS-CoV-2, form 2 | homo-2-mer | 4×GOL; 6×CL; | ||||
| Assess | ||||||
| Crystal structure of the ubiquitin-like domain 1 (Ubl1) of Nsp3 from SARS-CoV-2 | homo-2-mer | 13×EDO; 1×SO4; | ||||
| Assess | ||||||
| Structure of nonstructural protein Nsp9 from SARS-CoV-2 | homo-2-mer | 3×SO4; | ||||
| Assess | ||||||
| Full length SARS-CoV-2 Nsp2 | monomer | 3×ZN; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z17031… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z17419… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z69118… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z16501… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of ground-state model of SARS-CoV-2 helicase | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z14076… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z36432… | monomer | 1×VVD; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z32131… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z42604… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z14927… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z56923… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z57614… | monomer | 1×VWY; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z19819… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 helicase at 1.94 Angstrom resolution | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z15098… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z19739… | monomer | 1×VW1; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z45705… | monomer | 1×S9S; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z22936… | monomer | 1×VWM; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z21645… | monomer | 1×VVJ; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z11017… | monomer | 1×VX4; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z37376… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z28564… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z42538… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z12733… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z17456… | monomer | 1×S7J; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z14543… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z68299… | monomer | 1×JOV; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z28567… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z53860… | monomer | 1×STV; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z39638… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z16145… | monomer | 1×GQJ; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z36432… | monomer | 1×NZG; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z24758… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with POB0066 | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z28564… | monomer | 1×VWV; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z24672… | monomer | 2×VWJ; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z53825… | monomer | 2×VVG; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z28578… | monomer | 1×UVA; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z54226… | monomer | 1×NX7; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z26333… | monomer | 1×RYM; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z19735… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z23534… | monomer | 1×NY7; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z45617… | monomer | 1×JFM; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z14298… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z59181… | monomer | 1×VWG; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z82238… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z74475… | monomer | 1×JG4; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z28564… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 helicase in complex with Z2327226104 | monomer | 1×UJK; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z53116… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z85956… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z20270… | monomer | 1×K34; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z16660… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 helicase in complex with Z16391… | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 helicase in complex with AMP-PNP | monomer | 1×ANP; 3×ZN; 1×MG; | ||||
| Assess | ||||||
| SARS-CoV-2 Nsp2 | monomer | 3×ZN; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z12464656… | monomer | 3×ZN; 2×PO4; 1×LJ6; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP14 in the absence of NSP10 | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of ground-state model of SARS-CoV-2 NSP14 | monomer | 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z18490096… | monomer | 3×ZN; 2×PO4; 1×U1V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z10032072… | monomer | 3×ZN; 2×PO4; 2×LJR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z100643660 | monomer | 3×ZN; 2×PO4; 1×LFO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z54571979 | monomer | 3×ZN; 2×PO4; 1×O0S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z752989138 | monomer | 3×ZN; 2×PO4; 2×LMW; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z30061514… | monomer | 3×ZN; 2×PO4; 2×LQ3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z744930860 | monomer | 3×ZN; 2×PO4; 1×LJK; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z54615640 | monomer | 3×ZN; 2×PO4; 1×LK6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z65532537 | monomer | 3×ZN; 2×PO4; 1×LLU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z373768898 | monomer | 3×ZN; 2×PO4; 1×UWY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z274575916 | monomer | 3×ZN; 2×PO4; 1×WKS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z56983806 | monomer | 3×ZN; 2×PO4; 1×JJM; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z11860299… | monomer | 3×ZN; 2×PO4; 1×W0G; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z20737416… | monomer | 3×ZN; 2×PO4; 1×LO6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z20923709… | monomer | 3×ZN; 2×PO4; 1×LR9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z18162337… | monomer | 3×ZN; 2×PO4; 1×LNS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z437584380 | monomer | 3×ZN; 2×PO4; 1×I8D; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z383202616 | monomer | 3×ZN; 2×PO4; 2×LHR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z68277692 | monomer | 3×ZN; 2×PO4; 1×WH1; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z28564348… | monomer | 3×ZN; 2×PO4; 1×S5J; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z12474136… | monomer | 3×ZN; 2×PO4; 1×LPU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z20271587… | monomer | 3×ZN; 2×PO4; 1×WKA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z57258487 | monomer | 3×ZN; 2×PO4; 1×NVD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z32400357 | monomer | 3×ZN; 2×PO4; 1×NZJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z223688272 | monomer | 3×ZN; 2×PO4; 1×LGR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z57260516 | monomer | 3×ZN; 2×PO4; 2×B0V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z56880342 | monomer | 3×ZN; 2×PO4; 2×JGA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z22349203… | monomer | 3×ZN; 2×PO4; 1×VZS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z198195770 | monomer | 3×ZN; 2×PO4; 2×LJA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z56791867 | monomer | 3×ZN; 2×PO4; 2×K1S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z28564348… | monomer | 3×ZN; 2×PO4; 1×NZD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z15265047… | monomer | 3×ZN; 2×PO4; 1×LM6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z28564349… | monomer | 3×ZN; 2×PO4; 1×EJQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z28290384 | monomer | 3×ZN; 2×PO4; 1×WN1; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z13108766… | monomer | 3×ZN; 2×PO4; 2×U0V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z28564347… | monomer | 3×ZN; 2×PO4; 1×JGD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z71580604 | monomer | 3×ZN; 2×PO4; 1×LQV; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z32665176 | monomer | 3×ZN; 2×PO4; 1×LQI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z17960145… | monomer | 3×ZN; 2×PO4; 2×UX1; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z12724947… | monomer | 1×LF6; 2×PO4; 3×ZN; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z28564348… | monomer | 3×ZN; 2×PO4; 1×ELQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z28564349… | monomer | 3×ZN; 2×PO4; 1×AWD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z419995480 | monomer | 3×ZN; 2×PO4; 1×LRR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z20336378… | monomer | 3×ZN; 2×PO4; 2×LRF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z943693514 | monomer | 3×ZN; 2×PO4; 1×GT4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z57299529 | monomer | 3×ZN; 2×PO4; 1×LUY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z13543706… | monomer | 3×ZN; 2×PO4; 1×LKL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z466628048 | monomer | 3×ZN; 2×PO4; 1×O2M; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z256709556 | monomer | 3×ZN; 2×PO4; 2×60P; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z18998429… | monomer | 3×ZN; 2×PO4; 1×K1A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z13734456… | monomer | 3×ZN; 2×PO4; 1×SZE; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z10031465… | monomer | 3×ZN; 2×PO4; 3×LL0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z14306133… | monomer | 3×ZN; 2×PO4; 1×LKU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z126932614 | monomer | 1×T6J; 2×PO4; 3×ZN; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z32014663 | monomer | 3×ZN; 2×PO4; 1×WNV; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z12733121… | monomer | 3×ZN; 2×PO4; 1×O2A; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP14 in complex with 7MeGpppG. | monomer | 1×GTG; 3×ZN; 2×PO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z20726219… | monomer | 3×ZN; 2×PO4; 1×LQP; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 NSP14 in complex with Z28564349… | monomer | 3×ZN; 2×PO4; 1×7ZC; | ||||
| Assess | ||||||
| Structure of nsp14 from SARS-CoV-2 in complex with SAH | monomer | 1×SAH; 1×PEG; 1×TRS; 5×ZN; | ||||
| Assess | ||||||
| Crystal structure of the SARS CoV-2 Papain-like protease in complex with peptide inhibitor VIR250 | monomer | 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of the SARS CoV-2 Papain-like protease in complex with peptide inhibitor VIR251 | monomer | 1×ZN; | ||||
| Assess | ||||||
| Deep Mutational Scanning of SARS-CoV-2 PLpro | monomer | 1×ZN; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Papain-like protease PLpro | monomer | 1×ZN; 1×GOL; 2×CL; 1×PO4; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant | monomer | 1×ZN; 3×PO4; 2×CL; 2×GOL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Papain-like Protease bound to N-(2-pyrrolidyl)-3,4,5-trihydroxybenzoylhydra… | monomer | 1×DZI; 2×GOL; 1×ZN; 1×CL; 4×PO4; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Papain-like Protease bound to N-(3,4-dihydroxybenzylidene)-thiosemicarbazone | monomer | 1×A6Q; 2×GOL; 1×ZN; 5×PO4; 1×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Papain-like Protease bound to N-(3-methoxy-4-hydroxy-acetophenone)thiosemic… | monomer | 1×A3X; 5×GOL; 1×ZN; 3×CL; 3×PO4; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2 , P3221 space group | monomer | 1×ZN; 2×GOL; 2×PO4; 2×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Papain-like Protease bound to N-(2,4-dihydroxybenzylidene)-thiosemicarbazone | monomer | 5×GOL; 1×A4O; 1×ZN; 3×PO4; 5×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Papain-like Protease bound to N-(3,5-dimethoxy-4-hydroxybenzyliden)thiosemi… | monomer | 1×A5I; 2×GOL; 1×ZN; 5×PO4; 1×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Papain-like protease PLpro in complex with 4-(2-hydroxyethyl)phenol | monomer | 1×ZN; 3×CL; 1×YRL; 1×PO4; 1×GOL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Papain-like Protease bound to N-(2,5-dihydroxybenzylidene)-thiosemicarbazone | monomer | 1×A7L; 3×GOL; 1×ZN; 3×PO4; 3×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 Papain-like protease PLpro in complex with p-hydroxybenzaldehyde | monomer | 1×ZN; 8×CL; 1×HBA; 2×K; | ||||
| Assess | ||||||
| Crystal structure of the wild type SARS-CoV-2 papain-like protease (PLPro) with inhibitor GRL0617 | monomer | 1×TTT; 1×ZN; 2×SO4; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 PLpro with GRL0617 | monomer | 1×TTT; 2×ZN; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-69 | monomer | 1×Y61; 1×ZN; 3×SO4; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) bound to inhibitor XR8-65 | monomer | 1×ZN; 4×SO4; 1×Y97; | ||||
| Assess | ||||||
| SARS CoV-2 PLpro in complex with GRL0617 | monomer | 1×TTT; 3×ZN; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 papain-like protease (C111S mutant) | monomer | 1×DTT; 1×MLA; 1×ZN; 2×NA; 1×CL; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant, in complex with PLP_Sny… | monomer | 1×Y95; 4×ZN; 3×CL; 1×MES; 2×ACT; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Papain-like protease C111S | monomer | 1×ZN; 1×CA; | ||||
| Assess | ||||||
| Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with Jun9-84-3 inhibitor | monomer | 1×JWX; 1×ZN; 2×CL; 1×EDO; | ||||
| Assess | ||||||
| Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with PLP_Snyder630 inhibitor | monomer | 1×L30; 1×ZN; 4×CL; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with ebselen | monomer | 1×9JT; 1×ZN; 1×CL; 1×GOL; 6×IOD; 3×FMT; 1×NA; | ||||
| Assess | ||||||
| Papain-Like Protease of SARS CoV-2 in complex with Jun9-84-3 inhibitor | monomer | 1×JWX; 1×ZN; 1×CL; 2×EDO; | ||||
| Assess | ||||||
| Papain-Like Protease of SARS CoV-2 in complex with remodilin NCGC 390004 | monomer | 1×ZN; 3×YOO; 1×NA; 2×CL; 3×ACT; | ||||
| Assess | ||||||
| Papain-Like Protease of SARS CoV-2 in Complex with Jun9-72-2 Inhibitor | monomer | 1×JW9; 1×ZN; 1×EDO; | ||||
| Assess | ||||||
| Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with PLP_Snyder608 inhibitor | monomer | 1×9EI; 1×ZN; 2×CL; 2×FMT; | ||||
| Assess | ||||||
| Papain-Like Protease of SARS CoV-2 in complex with PLP_Snyder630 inhibitor | monomer | 1×L30; 1×ZN; 1×CL; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with PLP_Snyd… | monomer | 1×Y96; 4×ZN; 3×CL; 1×ACT; 1×MES; 13×UNX; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with PLP_Snyd… | monomer | 1×Y94; 4×ZN; 3×CL; 1×MES; 2×ACT; 12×UNX; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant, in complex with PLP_Sny… | monomer | 1×TTT; 4×ZN; 4×CL; 1×MES; 1×ACT; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant, at room temperature | monomer | 1×ZN; 1×PO4; 1×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) complex with covalent inhibitor Jun11313 | monomer | 1×Y3R; 1×SO4; 1×CL; 1×ZN; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 papain-like protease in apo form | monomer | 1×ZN; 1×CFF; 7×EDO; 3×SO4; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2 in complex with PLP_Snyder441 inhibitor | monomer | 1×Y41; 5×ZN; 4×CL; 1×ACT; 5×UNX; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2 , C111S mutant, in complex with PLP_Sny… | monomer | 1×VBY; 4×ZN; 1×MES; 3×CL; 1×ACT; | ||||
| Assess | ||||||
| The crystal structure of SARS-CoV-2 papain-like protease in complex with YM155 | monomer | 1×ZN; 1×CFF; 2×GXU; 5×SO4; 2×GOL; | ||||
| Assess | ||||||
| SARS-CoV-2 papain-like protease (PLpro) with inhibitor Jun12303 | monomer | 1×XXW; 1×GOL; 1×ACT; 5×ZN; 4×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 papain-like protease C111S mutant | monomer | 3×PO4; 4×GOL; 1×ACT; 1×ZN; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 papain-like protease | monomer | 2×GOL; 1×PO4; 1×ZN; 3×CL; | ||||
| Assess | ||||||
| Structure of SARS-CoV2 PLpro bound to a covalent inhibitor | monomer | 1×WUK; 3×ZN; 1×SO4; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2, C111S mutant, in complex with PLP_Snyd… | monomer | 1×Y41; 4×ZN; 2×CL; 2×ACT; 5×UNX; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2 in complex with PLP_Snyder530 inhibitor | monomer | 1×VBY; 4×ZN; 4×CL; 1×MES; | ||||
| Assess | ||||||
| The crystal structure of Papain-Like Protease of SARS CoV-2 in complex with PLP_Snyder496 inhibitor | monomer | 1×Y96; 4×ZN; 4×CL; 1×MES; | ||||
| Assess | ||||||
| X-ray structure of SCoV2-PLpro in complex with small molecule inhibitor | monomer | 3×PRL; 4×EDO; 1×ZN; 2×SO4; | ||||
| Assess | ||||||
| Mpro of SARS-CoV-2 in complex with the RK-68 inhibitor | monomer | 1×MIJ; 1×CL; | ||||
| Assess | ||||||
| SARS-CoV-2 Mpro in complex with D-4-38 | monomer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 main protease in complex with inhibitor MPI22 | monomer | 1×7Y2; | ||||
| Assess | ||||||
| SARS-CoV-2 main protease in a covalent complex with SDZ 224015 derivative, compound 5 | monomer | 5×DMS; | ||||
| Assess | ||||||
| SARS-CoV-2 Mpro (Omicron, P132H) free enzyme | monomer | |||||
| Assess | ||||||
| Room temperature In-situ SARS-CoV-2 MPRO with bound Z31792168 | monomer | 1×GWS; 1×DMS; | ||||
| Assess | ||||||
| Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified by in silico scree… | monomer | 1×4N0; | ||||
| Assess | ||||||
| crystal structures of diastereomer (S,S,S)-13b (13b-K) in complex with the SARS-CoV-2 Mpro | monomer | 1×O6K; 1×CL; | ||||
| Assess | ||||||
| A dual Inhibitor Against Main Protease | monomer | 1×5IL; | ||||
| Assess | ||||||
| Room temperature In-situ SARS-CoV-2 MPRO with bound Z1367324110 | monomer | 1×RZJ; 1×DMS; | ||||
| Assess | ||||||
| Room temperature In-situ SARS-CoV-2 MPRO with bound Z4439011520 | monomer | 1×UHV; 1×DMS; | ||||
| Assess | ||||||
| Room temperature In-situ SARS-CoV-2 MPRO with bound Z4439011584 | monomer | 1×UJ1; 1×DMS; | ||||
| Assess | ||||||
| Structure of Mpro complexed with Quercetin | monomer | 1×QUE; | ||||
| Assess | ||||||
| Structure of SARS-Cov2-Mpro-1-302 | monomer | |||||
| Assess | ||||||
| SARS-CoV-2 Mpro in complex with D-5-96 | monomer | 1×ACY; 1×ALA; 1×ILE; 1×V3E; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the non-covalent inhibitor GA-… | monomer | 1×LQ6; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the non-covalent inhibitor GC-… | monomer | 1×LQL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Main Protease in orthorhombic space group p212121 | monomer | 1×MLI; 1×NA; 1×CL; 2×DMS; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with Z-VAD-FMK | monomer | 1×DMS; 3×GOL; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 main protease (MPro) in complex with the inhibitor GD-9 | monomer | 1×OZI; | ||||
| Assess | ||||||
| SARS-CoV-2 3CLPro Peptidomimetic Inhibitor TPM5 | monomer | 1×40I; | ||||
| Assess | ||||||
| Crystal structure of the SARS-CoV-2 main protease in complex with Z-VAD(OMe)-FMK | monomer | 1×CL; | ||||
| Assess | ||||||
| The complex structure of mutant Mpro with inhibitor | monomer | 1×CL; | ||||
| Assess | ||||||
| The complex structure of WT-Mpro | monomer | 1×NA; | ||||
| Assess | ||||||
| Complex structure of Mpro with ebselen-derivative inhibitor | monomer | 1×SE; | ||||
| Assess | ||||||
| Crystal Structure of the CoV-Y domain of SARS-CoV-2 Nonstructural Protein 3 | monomer | 6×GOL; | ||||
| Assess | ||||||
| Crystal structure of SetMet CoV-Y domain of Nsp3 in SARS-CoV-2 | monomer | 5×SO4; 2×CL; | ||||
| Assess | ||||||
| The N-terminal crystal structure of SARS-CoV-2 NSP2 | monomer | 3×ZN; | ||||
| Assess | ||||||
| Crystal structure of the SARS-unique domain (SUD) of SARS-CoV-2 (1.35 angstrom resolution) | monomer | |||||
| Assess | ||||||
| Crystal structure of the SARS-unique domain (SUD) of SARS-CoV-2 (1.58 angstrom resolution) | monomer | 1×PO4; 1×LI; 4×GOL; | ||||
| Assess | ||||||
| Structure of nsp14 N7-MethylTransferase domain fused with TELSAM bound to SAH | monomer | 1×SAH; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 nsp14 methyltransferase domain in complex with the SS148 inhibitor | monomer | 1×6NR; 1×ZN; | ||||
| Assess | ||||||
| Structure of nsp14 N7-MethylTransferase domain fused with TELSAM bound to Sinefungin | monomer | 1×SFG; 1×ZN; 1×PEG; 1×EOH; 5×MOH; | ||||
| Assess | ||||||
| Structure of nsp14 N7-MethylTransferase domain fused with TELSAM bound to SAM | monomer | 1×ZN; 1×SAM; | ||||
| Assess | ||||||
| Structure of nsp14 N7-MethylTransferase domain fused with TELSAM bound to SGC0946 | monomer | 1×ZN; 1×AW2; | ||||
| Assess | ||||||
| Structure of nsp14 N7-MethylTransferase domain fused with TELSAM bound to SGC8158 | monomer | 1×ZN; 1×EOH; 1×MJ7; 1×K; | ||||
| Assess | ||||||
| Room-temperature X-ray structure of monomeric SARS-CoV-2 main protease catalytic domain (MPro1-196)… | monomer | 1×4WI; | ||||
| Assess | ||||||
| Room-temperature X-ray structure of monomeric SARS-CoV-2 main protease catalytic domain (MPro1-196)… | monomer | 1×K36; | ||||
| Assess | ||||||
| Room-temperature X-ray structure of monomeric SARS-CoV-2 main protease catalytic domain (MPro1-199) | monomer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 3CLpro catalytic domain | monomer | |||||
| Assess | ||||||
| Solution NMR structure of full-length Nsp1 from SARS-CoV-2. | monomer | |||||
| Assess | ||||||
| SARS-CoV-2 Macrodomain in complex with ADP-ribose | monomer | 1×APR; 1×NA; | ||||
| Assess | ||||||
| SARS-CoV-2 Macrodomain in complex with ADP-HPM | monomer | 1×A3R; 3×EDO; 1×NA; | ||||
| Assess | ||||||
| SARS-CoV-2 Macrodomain in complex with ADP-HPD | monomer | 2×A1R; 3×EDO; 1×GOL; 2×NA; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 NSP3 macrodomain in complex with ADPR | monomer | 1×APR; | ||||
| Assess | ||||||
| High-resolution structure of the SARS-CoV-2 NSP3 Macro X domain | monomer | |||||
| Assess | ||||||
| SARS-CoV-2 macrodomain Nsp3b bound to the remdesivir nucleoside GS-441524 | monomer | 1×U08; 2×EDO; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with MES | monomer | 1×MES; 5×EDO; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 macro domain in complex with ADP-ribose | monomer | 1×APR; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain (C2 crystal form, 100 K) | monomer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain (C2 crystal form, methylated) | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×HBD; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 macrodomain in complex with GMP | monomer | 1×5GP; 9×EDO; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 macrodomain in complex with adenosine | monomer | 3×EDO; 1×ADN; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 macrodomain in complex with ADP-ribose-phosphate (ADP-ribose-2'-pho… | monomer | 1×MG; 1×A2R; 2×EDO; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 macrodomain in complex with remdesivir metabolite GS-441524 | monomer | 1×U08; 3×EDO; | ||||
| Assess | ||||||
| Structure of the SARS-CoV-2 macrodomain (NSP3) in complex with ADP-ribose | monomer | 1×APR; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with HEPES | monomer | 3×EDO; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 (Covid-19) NSP3 macrodomain in complex with ADP-ribose | monomer | 1×APR; 6×EDO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×LZ1; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×1SQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4BY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×6P3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4JQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4BL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×ANN; | ||||
| Assess | ||||||
| Crystal Structure of ADP ribose phosphatase of NSP3 from SARS-CoV-2 in the apo form | monomer | 1×CL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×BVF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WB1; | ||||
| Assess | ||||||
| Crystal Structure of ADP ribose phosphatase of NSP3 from SARS CoV-2 in complex with AMP | monomer | 1×AMP; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×2AK; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×0LO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×AQO; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain (C2 crystal form, 310 K) | monomer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 (Covid-19) Nsp3 macrodomain in complex with TFMU-ADPr | monomer | 1×ZJ3; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain (P43 crystal form) | monomer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose (P43 crystal form) | monomer | 1×AR6; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 6 (P43 crystal fo… | monomer | 1×AR6; 1×CIT; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 10 (P43 crystal form) | monomer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 4 (P43 crystal fo… | monomer | 1×AR6; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 7 (P43 crystal fo… | monomer | 1×AR6; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 5 (P43 crystal fo… | monomer | 1×AR6; 1×CIT; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 9 (P43 crystal form) | monomer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 8 (P43 crystal form) | monomer | 1×ACT; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 7 (P43 crystal form) | monomer | 1×ACT; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 5 (P43 crystal form) | monomer | 1×CIT; 1×NHE; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 6 (P43 crystal form) | monomer | 1×CIT; 1×NHE; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at pH 4 (P43 crystal form) | monomer | 1×CIT; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 8 (P43 crystal fo… | monomer | 1×AR6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×CLW; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WYG; 1×S3E; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×Q3C; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×OHB; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4BL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×2CL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W6V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×6FZ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×OHP; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W6M; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×YTX; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×6OT; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W6P; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×Q6T; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WXO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×3EU; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×HQD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×NC3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×0LO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×HSM; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W5P; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×1FF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×PF0; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×7PD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×FHB; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×MOK; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4JO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W6D; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×XIY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×5HN; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×NMI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×APG; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W4Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×GVH; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×PYD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WXB; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×NCA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WXX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W6S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×6V9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4FS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W7V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×AOT; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×SHA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×FBB; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×1LQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×2D0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W7Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WY6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×07L; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WWT; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×BXW; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×JG8; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×3BZ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W5G; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×51X; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×AQO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×EXB; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×04R; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WXK; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W4V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×05R; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×0HN; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W8A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4FL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W51; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4J8; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×5ZE; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×54T; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W5M; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W6A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W8D; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×5OF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×06Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×JNZ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W5A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×PHB; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W57; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×BZX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×52F; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×PZA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WXT; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W4S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×HLR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×1SQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×8EJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×NOA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×W8J; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W5J; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WWH; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×KNL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4YS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×DMS; 1×WWN; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×XAN; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×HBD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4SV; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×EKZ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×3A9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×DFA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×TFA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W7S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W6G; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W5S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×54G; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 3×W3J; 2×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×2SX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×H35; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×3HP; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WYJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×W5D; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×6U6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×ZZA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×MYI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×LSA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×BHA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4SO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4BX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×4MB; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×TYZ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WYA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×3XH; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×MHW; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×3R6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WX7; 1×RZ9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S7F; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×DMS; 2×QVL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RGF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QJG; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QXS; 1×QY0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S7O; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WXD; 1×WXA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QWX; 1×QX5; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RIK; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WXJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×QIW; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QNF; 2×QNV; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×R0L; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QL6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×QZF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S6N; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QVC; | ||||
| Assess | ||||||
| PanDDA analysis -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with Z4718398507 - (… | monomer | 1×WQO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RFI; 1×RFU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QR0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×R8R; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S1F; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×DMS; 1×S6U; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QUR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WX4; 1×S1O; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WY7; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QVX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RI3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QJC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×QXC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RIZ; 1×RJ9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WXY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×2FX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×QYJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QU3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RDU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S6C; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QUC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RF0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WWP; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RG5; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QM6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QZO; 1×QZX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×RVS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QIO; 1×QIR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QLF; 1×QLU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QOR; 1×QP9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QMF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RXI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WW1; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×RZI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QQI; 1×QQR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RYI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×S5U; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QTO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RDN; 1×TFA; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WWJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S63; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×R8K; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QKL; 1×QKX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QZ6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×TFA; 1×DMS; 1×R9F; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RZR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QR6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WVM; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RW5; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S50; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QT6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RBO; 1×RC3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WW4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QTF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RCR; 1×RD6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QMO; 1×QN0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×R0H; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×RY6; 1×RYC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×R9L; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RWQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S3R; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×DMS; 1×QRU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QSL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RA3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WVY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S4O; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QT0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×RBB; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QQ9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×R8Z; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RYQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QJU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QYC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WVG; 1×WYY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S1X; 1×S2R; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×R9U; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RVO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S4F; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QS6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×NVU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S09; 1×S0T; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QO3; 1×QOF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×R0R; 1×R0W; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QJO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QXL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×R98; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QJ0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QWO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WXS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QK6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×R9F; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×QRC; 1×QRI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×QKC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QYO; 1×QYU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QW3; 1×QWC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RI7; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WXG; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×S5O; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RIW; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×QPL; 2×QPX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×QYJ; 1×QRU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WWS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×EVE; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RWL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×RXX; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×R0A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×WW0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RJL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RM6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RL5; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×ROO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RK9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RV3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RVF; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RNC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RTI; 1×RTU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RNL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RKU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RQ8; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RS9; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RLU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×RR3; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RP0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RSR; 1×RT5; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×WWH; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RK0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RQI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RQR; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RRF; 1×RS0; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RMU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 2×WWC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RLN; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RPU; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RQC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RKI; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex wit… | monomer | 1×RJS; | ||||
| Assess | ||||||
| Crystal Structure of ADP ribose phosphatase of NSP3 from SARS CoV-2 | monomer | 2×SO4; 1×NHE; | ||||
| Assess | ||||||
| Macro domain of SARS-CoV-2 in complex with ADP-ribose | monomer | 1×APR; | ||||
| Assess | ||||||
| Neutron crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P21 crystal form) | monomer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 10 (P43 crystal f… | monomer | 1×AR6; | ||||
| Assess | ||||||
| Crystal Structure of ADP ribose phosphatase of NSP3 from SARS-CoV-2 in complex with MES | monomer | 2×MES; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form, 73 kGy) | monomer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form, 153 kGy) | monomer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form, 290 kGy) | monomer | |||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form, 539 kGy) | monomer | |||||
| Assess | ||||||
| Structure of the SARS-CoV-2 NSP3 Macro X domain in complex with cyclic AMP | monomer | 1×CMP; | ||||
| Assess | ||||||
| SARS-CoV-2 Mac1 in complex with MDOLL-0169 | monomer | 1×PEG; | ||||
| Assess | ||||||
| Neutron crystal structure of SARS-CoV-2 NSP3 macrodomain at 293 K (P43 crystal form) | monomer | 1×NHE; | ||||
| Assess | ||||||
| Neutron crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at 293 K (C2 cr… | monomer | 1×APR; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ADP-ribose at pH 9 (P43 crystal fo… | monomer | 1×AR6; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of ground-state model of SARS-CoV-2 Nsp3 macrodomain | monomer | 2×EDO; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 2×3TR; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W04; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WRD; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W27; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WSY; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×GOV; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×7ZC; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W3A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition of ground-state model of SARS-CoV-2 Nsp3 macrodomain | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×K2G; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WQ4; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×T6J; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×DMS; 2×W3M; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×S7J; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×HRZ; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WQ7; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W2J; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WPS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WS4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WQM; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×4AP; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×GWP; 1×CL; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W2G; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×VZS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WRV; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WQA; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 2×BAQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WQY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W1A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×NXS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×JH4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WSJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×VZP; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×B1A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W21; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×GWV; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W0D; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WSG; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WQ1; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×VZM; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W41; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×L46; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WQG; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WOY; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W2V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W3Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W3P; 1×SO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×K41; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×GWY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WQV; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×VZY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×JHS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WRM; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WQJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W3D; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W1J; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W0Y; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×RZS; 1×NHE; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W3S; 1×SO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WPY; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WPV; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WRJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W3V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W17; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×DE5; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W3G; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W1D; 2×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W1V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×HGQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 2×K0G; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×HHQ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W1Y; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×JHJ; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W1M; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W0P; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×HYN; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×2OP; 1×LAC; 1×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×NZ1; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W0A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×WRY; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W34; | ||||
| Assess | ||||||
| Crystal structure of CoV-2 Nsp3 Macrodomain | monomer | 2×MLI; 1×MES; 1×GOL; 3×SO4; | ||||
| Assess | ||||||
| Crystal Structure of ADP ribose phosphatase of NSP3 from SARS CoV-2 in the complex with ADP ribose | monomer | 1×APR; 1×EDO; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 Nsp3 Macrodomain complex with PARG329 | monomer | 1×XB1; 1×BME; 3×SO4; | ||||
| Assess | ||||||
| SARS-CoV-2 NSP3 macrodomain in complex with aztreonam | monomer | 1×T6O; | ||||
| Assess | ||||||
| SARS-CoV-2 NSP3 macrodomain in complex with 1-methyl-4-[5-(morpholin-4-ylcarbonyl)-2-furyl]-1H-pyrr… | monomer | 1×EDO; 1×T6B; | ||||
| Assess | ||||||
| Crystal structure of CoV-2 Nsp3 Macrodomain complex with PARG345 | monomer | 1×XYJ; 4×SO4; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W1S; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W2A; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×W0V; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | |||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×JFP; 2×DMS; | ||||
| Assess | ||||||
| PanDDA analysis group deposition -- Crystal Structure of SARS-CoV-2 Nsp3 macrodomain in complex wit… | monomer | 1×S2S; | ||||
| Assess | ||||||
| SUD-C and Ubl2 domains of SARS CoV-2 Nsp3 protein | monomer | 2×CL; 1×P6G; 1×EDO; | ||||
| Assess | ||||||
| SARS-CoV-2 non-structural protein 10 (nsp10) variant T102I | monomer | 2×ZN; 3×CL; 1×DMS; | ||||
| Assess | ||||||
| Nonstructural protein 10 (nsp10) from SARS CoV-2 | monomer | 2×ZN; | ||||
| Assess | ||||||
| Nonstructural protein 10 (nsp10) from SARS CoV-2 | monomer | 2×ZN; 1×GOL; 3×CL; | ||||
| Assess | ||||||
| Non-structural protein 10 (nsp10) from SARS CoV-2 in complex with fragment VT00221 | monomer | 2×ZN; 2×DMS; 1×2AQ; 1×GOL; 2×CL; | ||||
| Assess | ||||||
| Non-structural protein 10 (nsp10) from SARS CoV-2 in complex with fragment VT00022 | monomer | 2×ZN; 2×DMS; 2×PIM; 2×GOL; 2×CL; | ||||
| Assess | ||||||
| Non-structural protein 10 (nsp10) from SARS CoV-2 in complex with fragment VT00239 | monomer | 2×ZN; 2×DMS; 1×X4V; 1×GOL; 3×CL; | ||||
| Assess | ||||||
| Non-structural protein 10 (nsp10) from SARS CoV-2 in complex with fragment VT00265 | monomer | 2×ZN; 1×7WA; 1×GOL; 1×DMS; 2×CL; | ||||
| Assess | ||||||
| Structure of N-terminal SARS-CoV-2 nonstructural protein 1 (nsp1) at atomic resolution | monomer | |||||
| Assess | ||||||
| SARS-CoV-2 non-structural protein-1 (nsp1) in complex with N-(2,3-dihydro-1H-inden-5-yl)acetamide | monomer | 1×QO6; | ||||
| Assess | ||||||
| Crystal structure of N-terminal SARS-CoV-2 nsp1 in complex with fragment hit 7H2 refined against an… | monomer | 1×OG3; | ||||
| Assess | ||||||
| Crystal structure of N-terminal SARS-CoV-2 nsp1 in complex with fragment hit 5E11 refined against a… | monomer | 1×NT9; | ||||
| Assess | ||||||
| SARS-CoV-2 non-structural protein-1 (nsp1) in complex with 4-(2-aminothiazol-4-yl)phenol | monomer | 1×92G; | ||||
| Assess | ||||||
| Crystal structure of N-terminal SARS-CoV-2 nsp1 in complex with fragment hit 11C6 refined against a… | monomer | 1×OF6; | ||||
| Assess | ||||||
| Structure of SARS-CoV-2 nonstuctural protein 1 | monomer | |||||
| Assess | ||||||
| SARS-CoV-2 non-structural protein-1 (nsp1) in complex with 2-(benzylamino)ethan-1-ol | monomer | 1×OEI; | ||||
| Assess | ||||||
| Crystal Structure of the N-terminus of Nonstructural protein 1 from SARS-CoV-2 | monomer | |||||
| Assess | ||||||
| Crystal structure of the nucleic acid binding domain (NAB) of Nsp3 from SARS-CoV-2 | monomer | |||||
| Assess | ||||||
| Crystal Structure of NSP1 from SARS-CoV-2 | monomer | |||||
| Assess | ||||||
| Crystal structure of the Nsp3 Y3 domain from SARS-CoV-2 | monomer | |||||
| Assess | ||||||
| Crystal structure of Ubl1 (residues 18-111) of SARS-CoV-2 | monomer | |||||
| Assess | ||||||
| Crystal structure of Ubl1 domain of nonstructural protein 3 of SARS-CoV-2 | monomer | 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of the Nsp3 bSM (Betacoronavirus-Specific Marker) domain from SARS-CoV-2 | monomer | |||||
| Assess | ||||||
| NMR structure of the N-terminal domain of Nsp8 from SARS-CoV-2 | monomer | |||||
| Assess | ||||||
| Solution structure of SARS-CoV-2 nonstructural protein 7 at pH 7.0 | monomer | |||||
| Assess | ||||||
| NMR solution structure of SUD-C domain of SARS-CoV-2 | monomer | |||||
| Assess | ||||||
52 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 5rfv.1.B | homo-2-mer | 0.91 | 2×T8J; | 100.00 | ||
| Assess | ||||||
| 5r7z.1.B | homo-2-mer | 0.91 | 2×HWH; | 100.00 | ||
| Assess | ||||||
| 6nur.1.A | monomer | 0.89 | 2×ZN; | 96.35 | ||
| Assess | ||||||
| 2z9j.1.A | homo-2-mer | 0.89 | 2×DTZ; | 96.08 | ||
| Assess | ||||||
| 6lu7.1.B | homo-2-mer | 0.89 | 100.00 | |||
| Assess | ||||||
| 6y2g.1.A | homo-2-mer | 0.88 | 1×GLY; 2×O6K; | 100.00 | ||
| Assess | ||||||
| 7jyy.1.A | monomer | 0.88 | 1×M7G; 1×SAM; | 100.00 | ||
| Assess | ||||||
| 2a5i.1.B | homo-2-mer | 0.87 | 2×AZP; | 96.08 | ||
| Assess | ||||||
| 6m71.1.A | monomer | 0.87 | 100.00 | |||
| Assess | ||||||
| 6wlc.1.E | homo-6-mer | 0.87 | 6×U5P; | 100.00 | ||
| Assess | ||||||
| 6w01.1.E | homo-6-mer | 0.86 | 100.00 | |||
| Assess | ||||||
| 5rlc.1.A | monomer | 0.86 | 3×ZN; | 100.00 | ||
| Assess | ||||||
| 7bv2.1.A | monomer | 0.86 | 2×ZN; 1×POP; | 100.00 | ||
| Assess | ||||||
| 7bq7.1.A | monomer | 0.86 | 1×SAM; | 100.00 | ||
| Assess | ||||||
| 7aap.1 |
Heteromer P0DTD1; | 0.86 | 2×ZN; 1×POP; | 100.00 | ||
| Assess | ||||||
| 6w4h.1 |
Heteromer P0DTD1; | 0.86 | 1×SAM; 2×BDF; 2×ZN; | 100.00 | ||
| Assess | ||||||
| 6nur.1 |
Heteromer P0DTD1; | 0.86 | 2×ZN; | 96.70 | ||
| Assess | ||||||
| 2h85.1.F | homo-6-mer | 0.85 | 88.12 | |||
| Assess | ||||||
| 7msw.1.A | monomer | 0.84 | 3×ZN; | 100.00 | ||
| Assess | ||||||
| 2rhb.1.A | homo-6-mer | 0.84 | 88.44 | |||
| Assess | ||||||
| 6ywk.3.A | monomer | 0.84 | 100.00 | |||
| Assess | ||||||
| 2xyq.1 |
Heteromer P0DTD1; | 0.83 | 1×SAH; 2×ZN; | 95.13 | ||
| Assess | ||||||
| 5nfy.1.A | monomer | 0.82 | 2×ZN; | 94.88 | ||
| Assess | ||||||
| 5wwp.1.A | monomer | 0.81 | 3×ZN; | 71.60 | ||
| Assess | ||||||
| 6m71.1.B | monomer | 0.80 | 100.00 | |||
| Assess | ||||||
| 6w9c.1.A | monomer | 0.80 | 1×ZN; | 100.00 | ||
| Assess | ||||||
| 2g9t.1.A | homo-12-mer | 0.80 | 24×ZN; | 97.12 | ||
| Assess | ||||||
| 3e9s.1.A | monomer | 0.79 | 1×TTT; 1×ZN; | 82.86 | ||
| Assess | ||||||
| 5c8s.1.B | monomer | 0.79 | 1×ZN; 1×MG; 1×SAH; 1×G3A; | 95.07 | ||
| Assess | ||||||
| 7cmd.4.A | monomer | 0.79 | 1×TTT; 1×ZN; | 100.00 | ||
| Assess | ||||||
| 7jlt.1.A | monomer | 0.79 | 100.00 | |||
| Assess | ||||||
| 5c8t.1.B | monomer | 0.79 | 2×ZN; 1×SAM; | 95.07 | ||
| Assess | ||||||
| 2w2g.1.A | monomer | 0.79 | 75.00 | |||
| Assess | ||||||
| 6wuu.2.A | monomer | 0.79 | 1×ACE; 1×ZN; | 99.69 | ||
| Assess | ||||||
| 1qz8.1.A | homo-2-mer | 0.79 | 97.35 | |||
| Assess | ||||||
| 6w4b.1.A | homo-2-mer | 0.79 | 100.00 | |||
| Assess | ||||||
| 5c8s.1 |
Heteromer P0DTD1; | 0.78 | 4×ZN; 1×MG; 1×SAH; 1×G3A; | 95.50 | ||
| Assess | ||||||
| 2ahm.1.H | monomer | 0.77 | 97.47 | |||
| Assess | ||||||
| 6w4h.1.B | monomer | 0.77 | 2×ZN; | 100.00 | ||
| Assess | ||||||
| 7jlt.1.D | monomer | 0.76 | 100.00 | |||
| Assess | ||||||
| 6nur.1.B | monomer | 0.76 | 97.47 | |||
| Assess | ||||||
| 7k7p.1.A | monomer | 0.76 | 100.00 | |||
| Assess | ||||||
| 2kqv.1.A | monomer | 0.75 | 78.13 | |||
| Assess | ||||||
| 2ahm.1.B | monomer | 0.75 | 98.80 | |||
| Assess | ||||||
| 2ahm.1 |
Heteromer P0DTD1; | 0.74 | 97.86 | |||
| Assess | ||||||
| 1uw7.1.B | homo-2-mer | 0.73 | 97.35 | |||
| Assess | ||||||
| 3vcb.1.A | homo-2-mer | 0.72 | 61.36 | |||
| Assess | ||||||
| 2kqw.1.A | monomer | 0.71 | 80.22 | |||
| Assess | ||||||
| 2ahm.1.E | monomer | 0.70 | 97.47 | |||
| Assess | ||||||
| 6m71.1.D | monomer | 0.70 | 100.00 | |||
| Assess | ||||||
| 2k87.1.A | monomer | 0.69 | 81.74 | |||
| Assess | ||||||
| 6zoj.1.8 | monomer | 0.67 | 100.00 | |||
| Assess | ||||||